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SUMMARY
Callophycolide A is a meroditerpene isolated from Callophycus serratus, a Fi-
jian red macroalgae. Callophycolide A has been shown to inhibit bacterial growth,
and it exhibits moderate cytotoxicity against multiple human cancer cell lines. Most
importantly, it exhibits moderate activity against Plasmodium falciparum, the dead-
liest malaria-causing parasite to humans. Due to its antimalarial action and the
need for antimalarial drugs on the pharmaceutical market, efforts toward a modular
approach to the total synthesis of callophycolide A are presented that incorporate in-
expensive, commercially available starting materials, offer gram-level scalability, and
utilize known chemistry, including copper-mediated aryl allylation, hydrolytic kinetic
resolution, base-promoted epoxide ring-opening, and the Steglich esterification. Once
completed, this synthetic pathway can be used as a template for the total synthesis
of other related marine natural products, such as the callophycols, callophycoic acids,
and the bromophycolides.
Callophycoic acids, also isolated from C. serratus, are the first examples of diterpene-
benzoic acids observed in macroalgae. In addition, these acids, particularly callophy-
coic acids G and H, exhibit modest antibacterial activity. Although they are not
strongly potent against malaria, they share a trans-decalin core identical to callophy-
cols A and B, which are halogenated diterpene-phenols isolated from C. serratus that
do exhibit modest antimalarial activity. Due to their identical core and their simpler
structure (i.e., trisubstituted olefin tail), if a divergent total synthesis of callophy-
coic acids G and H can be established, it can serve as a template for synthesizing
natural products that have been identified to be more potent against malaria, such
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as the callophycols, which are more complex in structure. Herein, a total synthesis
of callophycoic acids G and H is investigated, which consists of a Wittig reaction,
nucleophilic addition, and a bromonium-induced cation-pi cascade cyclization, and
the progress toward the target molecules in the current study will be disclosed.
To access chiral intermediates for the aforementioned metabolites, catalytic meth-
ods were sought. Hydrolytic kinetic resolution (HKR) resolves racemic epoxides using
water as the nucleophile and is most often catalyzed by chiral Co(III)-salens. Previ-
ous studies have shown that the counter-ion of the Co(III)-salen has a direct effect on
the rate of the HKR; when catalyzed by a 50:50 mix of (R,R)-Co(III)-salen-OH and
(R,R)-Co(III)-salen-SbF6, the fastest HKR rates occurred. It has further been shown
that the enantioselectivity is primarily associated with the reaction of (R,R)-Co(III)-
salen-OH on the activated epoxide. Based on the aforementioned origin of selectivity,
a catalyst containing a 50:50 mix of (R,R)-Co(III)-salen-OH and (±)-trans-Co(III)-
salen-SbF6 could, in principle, give high activities and enantioselectivities for HKR
comparable to a mixed counter-ion system containing both (R,R)-Co(III)-salens. In
this dissertation, a series of experiments are described that demonstrate that highly
selective catalysis is only achieved using 100% enantiopure ligand and that mixtures of
(R,R)-Co(III)-salen and (±)-trans-Co(III)-salen yield lower activity and selectivity.
Control experiments demonstrate that this is due to rapid counter-ion scrambling un-
der the reaction conditions, precluding the possibility of effectively co-utilizing enan-
tiopure (expensive) and racemic (inexpensive) catalysts with differing counter-ions.
The mechanistic investigations resolving the counter-ion scrambling are consistent
with the currently accepted mechanism for catalysis, involving cooperative activity
of the two Co(III)-salen species that activate the epoxide and water in the reaction.
Moreover, the application of HKR in the progress toward the total synthesis of callo-




1.1 Overview of malaria
Malaria is an extremely serious infectious disease; it is also one of the most ancient
diseases on Earth, with the first documentation of the disease’s symptoms dating
back to 3000 B.C. in ancient China. The disease, however, originated in Central
and West Africa over 10,000 years ago and was spread via the migration of man to
other countries, such as Northern Europe, Southeast Asia, the Mediterranean, and
the Americas [1, 2]. A total of 300-500 million malaria cases are reported annually,
with 1-2 million of these cases being fatal [3].
1.2 Causation and symptoms of malaria
The causation of malaria is through a protozoan parasite of the genus Plasmodium.
Specifically, five of the known 300 species cause malaria in humans: P. ovale, P.
malaria, P. vivax, P. knowlesi, and the most lethal malaria-causing parasite, P. fal-
ciparum [4, 5, 6] (Figure 1) [7].
P. falciparum is carried to the human host via the female Anopheles mosquito
(Figure 2): when one of these parasite-infected mosquitoes bites an uninfected hu-
man, it transfers sporozoites of the Plasmodium into the human bloodstream via
saliva. These sporozoites concentrate in the liver, where they grow into schizonts and
multiply. The infected liver cells will eventually rupture, thus releasing merozoites.
These merozoites infect the red blood cells (RBCs) of the human host, where they
reproduce asexually; it is here where symptoms of uncomplicated malaria, such as
vomiting, diarrhea, anemia, fever, and headaches, develop [4]. Once the schizonts
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Figure 1: Thin blood smear of P. falciparum gametocyte (reproduced from reference
[7]).
form in the RBCs, the RBCs rupture, releasing merozoites, which will either infect
new RBCs or will be converted into either male or female gametocytes [7, 4, 8, 9, 10].
Furthermore, note that in the more severe stages of malaria, RBCs containing these
mature schizonts can cause cerebral death and vascular occlusion via adhesion to the
walls of the capillary veins [4]. These gametocytes can be transferred to an unin-
fected Anopheles via biting a parasite-infected human host; once the gametocytes are
taken up by the Anopheles, they will reproduce sexually, eventually forming sporo-
zoites, which concentrate in the mosquito’s salivary glands; the aforementioned cycle
repeats upon biting an uninfected human host [7, 4, 8, 9, 10].
1.3 Treatments for malaria
Several methods have been used to eradicate malaria. In the 1950s, vector control
using pesticides, such as dichlorodiphenyltrichloroethane (DDT), eradicated malaria
from North America and the majority of Europe. As a result of the success of DDT,
2
Figure 2: Depiction of how the Plasmodium infects a human host with malaria
(reproduced from reference [8]).
several programs were launched that focused on eradicating malaria globally [1]. An-
timalarial drugs and widespread spraying of DDT were implemented globally [11]. As
a result of this global campaign, mortality rates significantly decreased, and by the
early-to-mid 20th century, only 10% of the global population was at risk of contracting
malaria [1].
Despite the aforementioned progress against malaria, the global eradication cam-
paign steadily declined due to events such as the ban on DDT, the evolution of
drug-resistant Plasmodium strains, and the emergence of mosquitoes that were resis-
tant to insecticides [12]. By the 1980s, 300-500 million cases of malaria were reported
annually, and in 2004, worldwide malaria fatalities peaked at 1,814,000 [13, 14, 15].
Through partnerships such as the World Health Organization (WHO) and Roll Back
Malaria (RBM) collaboration, malaria-related casualties have decreased by 32% since
2004, with 1,238,000 malaria-related fatalities in 2010 [15].
Although progress has been made in decreasing the number of malaria-related
casualties, this progress is delicate, as the Plasmodium adapts very well to inclement
conditions [4]. Moreover, drug-resistant Plasmodium strains are a continual threat
that could cause a malaria resurgence, even in epidemically controlled countries [4].
Therefore, continual funding and research in the prevention and treatment of this
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disease are paramount to preventing a pandemic [4].
As mentioned previously, vector control is a method used to prevent the spread
of malaria. Two of the most prominent methods are indoor residual spraying (IRS),
which are insecticides applied onto a dwelling’s inner surface, and long-lasting insecticide-
treated mosquito nets (LLINs or ITNs) or ”bed nets” [16]. With increased global
funding for the control of malaria, ITNs have been provided to areas that are at a
high risk for malaria infection, such as sub-Saharan Africa; consequently, approxi-
mately 75% of the at-risk population are protected against contracting malaria [17].
1.3.1 Quinoline derivatives
In addition to vector control, natural products, along with their synthetic deriva-
tives, have been the primary source for seeking malarial treatments [18]. Quinoline-
containing derivatives are commonly known as schizontocides, as they target and kill
schizonts, which are the predominant form of the Plasmodium in the intraerythrotic
infection stage [19]. The oldest group of antimalarials contain a quinoline group










Figure 3: Examples of historic antimalarial treatments that are quinoline derivatives.
All of the antimalarials derived from quinoline offer advantages and disadvantages,
which are due to their toxic side effects or the development of resistance [4]. These
disadvantages are commonly counterbalanced by pairing the quinoline derivative with
artemisinin or artemisinin derivatives [4].
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1.3.1.1 Quinine
The Cinchona tree bark component quinine, a quinoline methanol, was the first
antimalarial treatment (Figure 3) [20, 11], identified and isolated in 1820 [21]. For
nearly 200 years, quinine was the sole readily available treatment for malaria [21].
Although it has a somewhat low tolerability and efficacy, quinine is currently used
to treat multi-drug resistant strains of malaria [22, 23] and is one of the few drugs
recommended for the treatment of the most severe forms of malaria [22]. Moreover,
it can be administered to patients via an intravenous solution if they cannot tolerate
the oral formulation [22].
1.3.1.2 Chloroquine
As mentioned previously, quinine was used for nearly 200 years to treat malaria [21].
First synthesized in 1934, the 4-amino quinoline drug chloroquine (Figure 3) then re-
placed quinine in the 1940s, becoming commercially available in 1946 [4, 20]. Chloro-
quine was widely used following World War II, and it was the first line treatment for
malaria worldwide for 50 years [21]. Chloroquine, during its peak in popularity, was
highly effective against many of the Plasmodium strains. Moreover, its pharmaceu-
tical properties, including high patient tolerance, as well as greater effectiveness and
lower toxicity relative to quinine, contributed to the drug’s popularity, as well as its
low production costs [24, 22, 23].
Chloroquine was commonly delivered in the form of its diphosphate salt (CQDP),
whose side effects include dizziness, nausea, headaches, and double vision [23]. In the
effort to eradicate malaria worldwide, chloroquine was widely distributed, included in
table salt stocks around the world as a prophylactic [24]. This world distribution in
table salt most likely contributed to the parasite’s resistance to the drug in the late
1950s, effectively destroying its therapeutic efficacy [4].
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1.3.2 Mode of action (MOA) of quinoline-containing antimalarials
As mentioned previously, quinoline-containing antimalarials are solely active against
the intraerythrocytic parasite stage of infection, thus clearing the Plasmodium from
the bloodstream [25]. Once the Plasmodium enters the RBCs, it is surrounded by
human hemoglobin (Hb), which is ingested by the parasite, thus engulfing it into its
digestive vacuole, with a pH ranging from 5.0-5.4 [26, 27]. Once Hb is ingested by the
parasite, it is exposed to many diverse proteases that specialize in degrading the Hb
tetramer [9], thus supplying the parasite with the essential amino acids for its growth
and its maturation and is therefore crucial for Plasmodium survival [26, 27]. As a
result, this essential Hb catabolism is a logical target for treatments against malaria.
Hb proteolysis results in free heme being released as waste; once this free heme is
released, the Fe2+ center is oxidized to Fe3+, forming ferriprotoporphyrin IX (Fe(III)PPIX,
Figure 4) [4], which is toxic to the Plasmodium, resulting in enzyme inhibition, mem-
brane peroxidation, the formation of radicals that are free of oxygen and reduced
leukocyte function, as the P. falciparum has little to no heme oxygenase to effectively
catabolize the free heme [28]. However, the parasite circumvents the effects of this
toxicity by crystallizing the heme, thus converting it to hemozoin (Figure 4) [4], a
five-coordinated (Fe(III)PPIX)2 dimer in a crystalline arrangement that are linked
via the propionate side-chains of the adjacent monomers; these Fe(III)PPIX dimers
connect to other Fe(III)PPIX dimers via hydrogen bonds [29, 30, 31]. Thus, it is
logical that the mode of action (MOA) for antimalarials is to interrupt this hemo-
zoin formation, which should lead to a buildup of heme that will ultimately kill the
parasite.
The MOA of antimalarials derived from quinoline targets the interruption of hema-
zoin formation [25, 32]. Taking the weakly basic chloroquine (CQ) as an example






























Figure 4: Figure depicting the structures of Fe(III)PPIX and a hemozoin dimeric
unit [4].
diffuse across the membrane of the food vacuole (Figure 5) [4]. Once inside the Plas-
modium food vacuole, which is acidic, the amount of protonated CQ increases and
thus becomes trapped within the vacuole, as it is now ionic [19]. Consequently, the
protonated CQ can either bind the Fe(III)PPIX or the crystallized hemozoin. Both of
these pathways result in the interruption of the hemozoin crystallization process; con-
sequently, free heme begins to build up in large concentrations. This buildup of heme
results in destruction of the membrane of the digestive vacuole and consequently in
the death of the Plasmodium [4, 19, 33, 34, 35]. Over time, however, the food vacuole
of the Plasmodium evolves such that the transmembrane proteins undergo a muta-
tion that allows the quinoline derivative to be pumped out of the food vacuole, thus
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resulting in the drug being inactive [4, 19, 33, 34, 35, 36].




Artemisinin is a natural product that was isolated from the Chinese sweet worm-
wood Artemisia annua in the early 1970s [14] and was first synthesized in 1983 [37].
Structurally, it is a sesquiterpene lactone with an endoperoxide bridge within a seven-
membered ring system (Figure 6) [38, 39]. Although once deemed too expensive for
commercial pharmaceutical production [37], artemisinin has been significant in treat-
ing malaria over the past 20 years. Artemisinin is currently the most fast-acting,
potent drug available, with an IC50 value of >7nM [38, 39], and thus, it is the rec-
ommended treatment for malaria caused by P. falciparum [40]. The efficiency of
artemisinin against P. falciparum can be attributed to the fact that it is rapidly elim-
inated from the bloodstream of the host (t1/2 = <1 h) [41]; this rapid elimination
helps to minimize the chance of building resistance [4]. Consequently, artemisinin-
based drugs must be taken frequently to maximize their effects and thus they are
commonly used together with other antimalarial drugs with a different MOA, better









IC50 = 7 nM
Figure 6: Artemisinin, the most fast-acting, potent drug available to-date against
malaria [38, 39].
1.3.3.1 MOA of artemisinin and derivatives
Unlike the quinoline-based antimalarials, which act on the erythrotic state of parasite
infection, artemisinin displays antiplasmodial effects at multiple stages of the infection
by the Plasmodium (which contributes to its potency), including the liver, erythrotic,
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and the sexual stages; it is in the sexual stage where the gametocytocidal agents
kill gametes of the parasite inside the gut of the mosquito, thereby decreasing the
rate of transmission [43]. Structure-activity relationship (SAR) studies, however,
have attributed the endoperoxide bridge as being essential to its antimalarial activity
[37, 41]. Furthermore, in contrast to the quinolines, artemisinin does not bind to the
hemozoin crystals, thus inhibiting its formation; rather, it forms adducts with the
hemozoin, as well as additional biological macromolecules, such as the translationally
controlled tumor protein (TCTP) [44]. This binding serves as a catalyst for the
breakdown of the labile endoperoxide bridge. The breakdown of this bridge results in
the formation of free radicals, the alkylation of parasitic proteins, and fatal damage
to the membrane systems of the parasite [45].
1.3.3.2 Drawbacks to the use of artemisinin
Although artemisinin is currently the most potent-acting drug available to treat P.
falciparum-related malaria, there are several drawbacks to this drug, in addition to its
fast clearance from the body [41]. The shortage of the Chinese sweet wormwood, low
yield of production, and costly semi-synthetically produced artemisinin and deriva-
tives cause the drug to not be readily available [46]. Moreover, because its MOA
involves a free-radical mechanism, the potential of artemisinin to be neuro- and cu-
mulatively toxic is likely [4]. With artemisinin resistance on the rise, there is an
urgent need to pursue alternative antimalarial treatments.
Currently, for patients with uncomplicated malaria (stemming from P. falci-
parum), the recommended first-line treatment consists of ACT [40], which combines
artemisinin or its derivatives with a second drug that has a differing MOA to am-
plify efficacy while minimizing the potential of the parasite developing resistance [42].
However, artemisinin and its derivatives are at risk for parasite resistance, as there
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have been reports of P. falciparum resistance toward artemisinin in Vietnam, Thai-
land, Myanmar, and Cambodia [47]. Although the efficacies of these ACTs have
yet to be compromised, should they fail, there are currently no alternatives to treat
malaria because the present options in the pipeline are also derivatives of artemisinin,
which would potentially give rise to similar resistance [4].
1.4 Potential alternatives to treat malaria
1.4.1 Antimalarial diterpenes
In investigating alternatives for treating malaria, several diterpenes have been iso-
lated and tested for antimalarial activity. Specifically, diterpene lactones, such as
the compounds isolated from Parinari capensis (1 - 3, Figure 7) [48, 49], displayed
promising activity against malaria, with IC50 values of 0.54, 0.67, and 1.57 µM, respec-
tively. However, due to their toxicity, further investigations regarding their biological











4; R1 = Ac, R2 = H
5; R1 = Ac, R2 = OH
6; R1 = COC3H7, R2 = OH 
7; R1 = COC3H7, R2 = Ac
1; R  = OMe
2; R = OH
3; R = H
Figure 7: Examples of diterpene lactones isolated from Parinari capensis and bri-
arellins [48, 49].
Other diterpene lactones from the eunicellin class, briarellins (4 - 7, Figure 7)
[48, 49], displayed activity against malaria (IC50 = 15.0, 9.0, 9.0, and 8.0 µM, re-
spectively); this activity was attributed to the presence of the -OR group at the
C-6 position [49]. Thus, activity against malaria can be attributed to the diterpene
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lactone structures.
1.4.1.1 Diterpenes isolated from Callophycus serratus
In 2005, Kubanek et al. discovered a class of compounds from Callophycus serratus, a
Fijian red macroalgae [50]. Through several liquid-liquid partitioning steps, followed
by normal and reverse-phased HPLC fractionation [51, 52, 53], they were able to
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IC50 = 2.1 µΜ
Bromophycolide H; R = Br (R)
IC50 = 0.9 µΜ
Bromophycolide I; R = OH (S)
IC50 = 2.5 µΜ
Figure 8: Benzoate diterpenoids isolated from C serratus [50, 51, 52, 53, 54].
Characterization of the compounds using X-ray crystallography, NMR, and MS
revealed that each of these compounds contained a novel diterpene-benzoate struc-
ture [50]. The group has since isolated multiple benzene diterpenoids, including 21
bromophycolides [50, 51, 52, 53], debromophycolide A [50], eight callophycoic acids
[55], five bromphycoic acids [56], two callophycols [55], and callophycolide A (Figures
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Callophycoic Acid G; X = H







Callophycol A; X1=Br X2=Cl
Callophycol B; X1=Cl, X2=Br
H
Figure 9: Diterpene-benzoic acids and diterpene-phenols isolated from C. serratus
[55, 56].
All of the bromophycolides display varying activity against P. falciparum; the
most potent ones being the bromophycolides, with IC50 values ranging from 0.3 to
0.9 µM; therefore, with respect to antimalarial activity, the lactone macrocycle is
a critical component of the SAR between the aforementioned natural products and
their activities against P. falciparum (Figure 8) [50, 51, 52, 53]. Consequently, the
aforementioned natural products isolated from C. serratus could potentially serve as
alternative antimalarial treatments, as resistance to artemisinin is increasing.
Of the bromophycolides isolated, bromophycolide A was found in the greatest
abundance (0.8% plant dry mass) [50]. Thus, bromophycolide A was the most logical
starting point for biological activity studies. Bromophycolide A was determined to
have an IC50 value of 0.7 µM against P. falciparum [5]. To investigate the MOA
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of bromphycolide A, the macrolide was modified with the addition of immunoaffinity
fluorescent (IAF) tags (Figure 10) [5] via a Steglich esterification, and the IAF-tagged
bromophycolide A molecules were used to determine the intracellular distribution
of this probe in erythrocytes infected by P. falciparum [5]; it was observed that
















Figure 10: Bromophycolide A molecule tagged with an IAF [5].
This probe was also used in co-incubation studies and multichannel fluorescence
confocal microscopy. It was determined that the probe associated with intracellular
neutral lipids [5]. As hemozoin formation occurs inside lipid nanospheres, it was sug-
gested that bromophycolide A could be targeting the crystallization of heme. When
tested for the inhibition of heme crystallization, bromophycolide A inhibited this pro-
cess, with an IC50 of 2.5 molar equivalents of bromophycolide to heme. Absorbance
spectroscopy of Fe(III)PPIX in the presence of bromophycoide A resulted in a decrease
in the Soret band of Fe(III)PPIX by 45%, which further suggests that bromophycolide
A targets heme crystallization. Moreover, bromophycolide A was found to be active
against the chloroquine-resistant strain Dd2, with an IC50 value of 0.377 µM, thus
unrecognizable with respect to the parasite efflux system [5].
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1.4.1.2 Drawbacks to using C. serratus-isolated compounds as antimalarials
Currently, the likelihood of these natural products becoming active pharmaceutical
ingredients (APIs) for antimalarial drugs is limited. The vast majority of these com-
pounds from C. serratus comprise less than 0.01% of the plant dry mass, leading to
only milligrams of isolated pure product; several grams are required to fully investi-
gate biological activity. Thus, the current protocol for obtaining these pure benzene
diterpenoids is not practical or efficient. Therefore, other avenues must be explored
to obtain these compounds in usable quantities. Although there have been investiga-
tions into the syntheses of the bromophycolide A and D skeleta [57], there are, to our
knowledge, no known divergent total syntheses of bromophycolide A.
1.4.1.3 Addressing the drawbacks of the aforementioned antimalarials
As shown in Figure 8 [50, 51, 52, 53, 54], the bromophycolide macrocycles are either
15- or 16-membered and all contain a para-hydroxybenzoate moiety. However, despite
these similarities, these structures are also very diverse in that some contain vary-
ing bromocyclohexene moieties, tetrahydropyran rings, oxirane rings, and tert-butyl
moieties. Due to this structural complexity, a rational approach toward the synthesis
of the macrolides, such as bromophycolide A, would be to investigate the synthesis
of an alternative diterpene-benzoate that is simpler in structure, as this will allow
for similar, if not the same, synthetic steps to be determined and optimized before
focusing on the more structurally complex meroditerpenes. Callophycolide A is also
a 15-membered macrolide isolated from C. serratus ; although not as potent as bro-
mophycolide A (IC50 = 5.2 µM) [54], it has a more simplistic macrolide skeleton, with
only two stereocenters and no bromine atoms, cyclohexenes, or cyclic ether moieties
present (Figure 11) [50, 54].
Thus, if a total synthesis of callophycolide A could be accomplished, some of the















Figure 11: Structural comparison of the macrolides bromo- and callophycolide A
[50, 54].
structurally complex bromophycolides that are more potent against malaria.
1.4.1.4 Callophycoic acids G and H and callophycols A and B
With respect to diterpenes with simpler structures, callophycoic acids are another
class of diterpenes isolated from C. serratus (Figure 8) [50, 51, 52, 53, 54]. These
were the first examples of diterpene-benzoic acids that were observed in macroalgae
[55]. They do not express significant potency against malaria (IC50 >100 µM) [55];
however, they do display modest antibacterial activity, namely, callophycoic acids G
and H (>10-63.9 µM and 27.4- >50 µM, respectively, against Staphylococcus aereus,
Enterococcus faecium, and tubuclar bacteria) [55]. They also share a similar trans-
decalin core to callophycols A and B, which are halogenated diterpene-phenols that
are potent against malaria (relative to callophycoic acids G and H), with IC50 values of
35.7 and 40.7 µM, respectively [55]. Due to this similar core and simpler trisubstituted
olefin tail, a divergent total synthesis of callophycoic acids G and H can serve as a tem-
plate to synthesize callophycols A and B. Regarding a biosynthetic pathway for the
synthesis of the trans-decalin core of the diterpene-benzoic acids and phenols, it was
proposed that it was formed via halogenation of the compounds at their electrophilic
sites, which can be achieved by vanadium haloperoxidase. However, a drawback of
catalysis via vanadium haloperoxidase is the low specificity in the formation of the
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bromine-carbon bond [58]. Snyder’s group has synthesized and utilized bromodiethyl-
sulfonium bromopentachloroantimonate(V) (BDSB), an electrophilic bromine source,
to form bromonium ions and thus promote stereoselective bromonium-induced cation-
pi polyene cyclizations of electron-deficient terpenes derived from geraniol, nerol, and
farnesol (Figure 12) [59], forming the respective cyclohexanes/enes and cis- and trans-















Figure 12: Example of a stereoselective bromonium-induced cation-pi cyclization
using BDSB [59].
If the reaction conditions concerning the trans-decalin formation can be deter-
mined for callophycoic acids G and H using BDSB, then this would serve as a more
stereospecific alternative to the syntheses of this family of metabolites.
1.5 Overall thesis goals
To access the chiral intermediates for the aforementioned C. serratus metabolites,
catalytic methods were sought. Hydrolytic kinetic resolution (HKR) is a method for
resolving racemic, terminal epoxides using water as the nucleophile; it is most often
catalyzed by chiral Co(III)-salens and can be used to synthesize chiral intermediates
for active pharmaceutical ingredients (APIs) [61, 62, 63]. Because a chiral, terminal
epoxide can be utilized in the total synthesis of some of the above natural products,
the application of HKR will be presented. Thus, this thesis consists of two parts:
the first part regards metallosalens and the Co(III)-salen-catalyzed hydrolytic kinetic
resolution (HKR), and the other regards the progress toward the syntheses of five
different diterpenes isolated from the Fijian red macroalgae Callophycus serratus.
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Chapter two presents the evaluation of enantiopure and non-enantiopure Co(III)-
salen catalysts and their counter-ion effects in the HKR of racemic epichlorohydrin.
Catalysis of HKR via chiral Co(III)-salens occurs via a bimetallic mechanism, where
Co(III)-salen-X activates the electrophilic epoxide and Co(III)-salen-OH serves as
the nucleophile-delivering complex to the activated epoxide. Because each epoxide
enantiomer binds to Co(III)-salen-X with equal affinity, studies were conducted to de-
termine whether the salen ligand for Co(III)-salen-X must be enantiopure. The results
showed that the HKR with 50% racemic Co(III)-salen-SbF6 did not lead to highly
active and enantioselective catalysis, which was due to the counter-ion scrambling
between the Co centers. Chapter three describes the progress toward the synthesis
of callophycolide A. Regarding callophycolide A, the chapter will show the specifics
of the successful syntheses of various intermediates. Specifically, it will showcase the
potential use of Co(III)-salen-catalyzed HKR to access a chiral epoxylinalool moiety
that is otherwise difficult to access in high yields. In addition, the troubleshooting
behind the base-promoted epoxide ring-opening step will also be discussed. Chapter
four will discuss the progress toward the syntheses of callophycoic acids G and H and
callophycols A and B. Specifically, access to the trans-decalin core that is common to
these four compounds will be described, as well as investigations of a model system to
determine and optimize their endgames (final stages of the syntheses). Finally, chap-
ter five summarizes the findings of both the HKR and natural product total syntheses
and suggests multiple paths forward for the aforementioned projects.
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CHAPTER II
EVALUATION OF ENANTIOPURE AND
NON-ENANTIOPURE Co(III)-SALEN CATALYSTS AND
THEIR COUNTER-ION EFFECTS IN THE
HYDROLYTIC KINETIC RESOLUTION (HKR) OF
RACEMIC EPICHLOROHYDRIN
The research presented in this chapter is published data from Key, R. E.; Venkata-
subbaiah, K.; Jones, C. W. J. Mol. Catal. A: Chemical, 2013, 366, 1.
2.1 Introduction
Kinetic resolution separates a racemic mixture into its enantiomers based on the
differential reaction rates of each enantiomer. This reaction requires an enantiomeri-
cally pure reagent to effectively resolve the enantiomeric pair [64]. Hydrolytic kinetic
resolution (HKR) is a well-established technique used to resolve racemic epoxides,
specifically terminal epoxides, into a single enantiomer via a ring-opening reaction














Figure 13: HKR of racemic epichlorohydrin using a Co(III)-salen catalyst 1-4 [61].
HKR was discovered serendipitously by the Jacobsen group while investigating Co-
salen-catalyzed enantioselective meso-epoxide ring-opening reactions using carboxylic
acid nucleophiles (see Figure 14) [65]. During these investigations, they observed both
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1) contamination from water, thus forming a 1,2-diol byproduct in high enantiomeric
excess (ee), and 2) acetic acid contamination in commercial grade 1-hexene oxide
used in the experiments [66] oxidized the Co(II) complex to the active Co(III) com-
plex. Expanding on their HKR discovery, an optimal method for the syntheses of
enantioenriched terminal epoxides was sought, as at that time, there were no useful
methods that existed for the direct formation of these types of epoxides [66]. Toku-
naga et al. determined that their newly discovered HKR reaction was suitable for
the synthesis of a variety of enantioenriched terminal epoxides, such as propylene
oxide, 1-octene oxide, epichlorohydrin (ECH), and 1-hexene oxide, with high yields











77% ee, 98% yield
98% ee, 75% isolated yield (when recrystallized 
from DCM/heptane)
Figure 14: Co(II)-salen-catalyzed enantioselective ring-opening of cyclohexene oxide
using benzoic acid [65].
The HKR of terminal epoxides has attracted widespread interest for a number of
reasons. From a synthetic chemistry perspective, the strained, reactive, and three-
membered ring functionality makes enantiopure epoxides a useful chiral building block
for a multitude of reactions [62]. In addition, the coproduct of the reaction, a chiral
diol, can be a useful building block as well, being used, for example, in the synthesis
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Table 1: Initial study, performed by Jacobsen’s group, of the Co(III)-salen-OAc-
catalyzed HKR of racemic terminal epoxides demonstrating moderate yields, high
















Entry R Loading (mol %) Water (equiv.) Time (h) Epoxide ee (%) Epoxide yield (%) Diol ee (%) Diol yield k rel
a
1 CH3 0.20 0.55 12 >98 44 98 50 >400
2 CH2Cl 0.30 0.55 8 98 44 86 38 50
3 (CH2)3CH3 0.42 0.55 5 98 46 98 48 290
4 (CH2)5CH3 0.42 0.55 6 99 45 97 47 260
5 Ph 0.80 0.70 44 98 38 98b 39b 20
6 CH=CH2 0.64 0.50 20 84 44 94 49 30
7 CH=CH2 0.85 0.70 68 99 29 88 64 30
akrel (selectivity factor) is determined by the equation ln[(1-C)(1-ee)]/ln[(1-C)(1+ee)], where C = conversion and ee = enantiomeric excess[67].
bDenotes ee and isolated yield after recrystallization.
of active pharmaceutical ingredients (APIs), such as muconin, an anticancer agent,
as shown in Figure 15 [68, 69, 62, 63].
Moreover, with respect to pharmaceutical significance, a macrocyclic Co(III)-
salen-PF6 has been used as a catalyst in HKR to produce the enantiopure terminal
epoxides (S )-1-naphthyl glycidyl ether and (S )-propene oxide to be used in the syn-
theses of the chiral drugs (R)-mexiletine and (S )-propranolol, respectively (Figures
16 and 17, respectively) [70]. HKR is a simple, straightforward method for preparing
a variety of highly enantioenriched terminal epoxides from inexpensive materials that
would otherwise be difficult to access [62]. Many epoxides are commercially available
as racemic mixtures, making a kinetic resolution for a single epoxide enantiomer ap-
pealing. The only reagent required for HKR is water, which is safe and inexpensive
[61]. From a catalysis science perspective, the Co(III)-salen-catalyzed HKR reaction
has become a useful test-bed for the development of supported catalysts that en-
hance cooperative catalysis, as the HKR reaction is now the prototypical cooperative



























Figure 15: Synthesis of the anticancer agent muconin [68, 69].
2.1.1 Co(III)-salen catalysis of HKR occurs via a bimetallic/cooperative
mechanism
Using chiral Co(III)-salen-X (X = nucleophilic counter-ions, such as Cl, OAc) com-
plexes, Jacobsen and Blackmond showed that the reaction typically follows a second-
order, cooperative bimetallic pathway (where two cobalt centers participate in the
rate-determining step of the reaction) [72, 73, 74, 75]. In this proposed mechanism,
one Co(III)-salen (presumed to have the original counter-ion, X) activates the elec-
trophilic epoxide, while the other Co(III)-salen (presumed to have an OH− counter-
ion) activates the nucleophilic water (Figure 18, red pathway) [72, 74, 75].
The Co(III)-salen-OH is a hypothetical species, first proposed by Nielsen et al.
[72]. This active species has yet to be isolated or conclusively characterized. Kem-
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Figure 16: HKR of (S )-1-naphthyl glycidyl ether and (S )-propene oxide using macro-
cyclic Co(III)-salen-PF6 [70].
the coordination, conformational, and electronic properties of Co(III)-salens to bet-
ter understand the enantioselectivity of HKR [76]. They determined that for the
bimetallic transition state exemplified by the two Co(III)-salens in HKR, the nu-
cleophilic Co(III)-salen-OH exists as a pentacoordinated, high spin, paramagnetic
complex, and the Co(III)-salen-X (X 6= OH) that activates the epoxide exists as a
hexacoordinated, low spin, diamagnetic complex [76]. The two Co(III)-salens are
aligned in a ”head-to-tail” orientation [66]. Due to this orientation, the Co(III)-
salen-OH can attack one epoxide enantiomer over the other [76]. Recently, Vinck
et al. proposed that a small fraction of the Co(III)-salen-OAc species in HKR is a













































Figure 17: Applications of HKR-synthesized enantiopure terminal epoxides used for
the syntheses of chiral drugs (R)-mesitylene and (S )-propranolol [70].
acid present (Figure 19) [77]. This radical, which has one to two acetates ligated
to the complex, is proposed to have formed via a two-electron, two-proton reduction
of oxygen to hydrogen peroxide, thus producing a delocalized phenoxyl radical that
is stabilized by the bulky tert-butyl groups located at the ortho- and para-positions
of the phenolate [77]. The radical was characterized by pulsed and continuous-wave
electron paramagnetic resonance (EPR), as well as resonance Raman (RR) [77].
2.1.2 Rate of HKR: dependent upon the Co(III)-salen counter-ion
Nielsen et al. demonstrated that the nucleophilicity of the Co(III)-salen counter-
ion had a direct and important effect on the rate of HKR [72]. At low catalyst
loadings, it has been reported that there is a less selective, monometallic pathway that
competes with the bimetallic pathway [78]. Taking the nature of the Co(III)-salen





































Figure 18: Scheme of the mechanism that shows the presence of the proposed
monometallic (blue) and bimetallic (blue coupled with red) pathways in HKR [72, 73].
pathway (Figure 18, blue pathway) [73] couples with the bimetallic pathway (Figure
18, red pathway) [72] when Co(III)-salens with highly non-nucleophilic counter-ions
are present in the reaction. For the bimetallic pathway, the hypothetical Co(III)-
salen-OH is formed in situ from Co(III)-salen-X (X 6= OH) via a nucleophilic attack
(by the counter-ion X) on the epoxide (Figure 18, black pathway) [72].
If X− is a good nucleophile, such as Cl−, the counter-ion will rapidly add to the
epoxide in the black pathway, and water is suggested to produce the hypothetical
Co(III)-salen-OH. With an accumulation of Co(III)-salen-OH occurring in the HKR
reaction, the catalytic activity decreases because Co(III)-salen-OH is a poorer Lewis
acid than Co(III)-salen-X (X 6= OH) [72]. If X = OTs, HKR catalysis is highly effi-
cient, as counter-ion addition is reversible because Co(III)-salen-OTs is not suggested









































Figure 19: Scheme of the formation of the proposed Co(III)-bound phenoxyl radical
that is formed in small amounts via air oxidation of Co(II)-salen in the presence of
acetic acid [77].
SbF6
−, there should be no nucleophilic attack of the counter-ion on the epoxide, and
thus, no generation of Co(III)-salen-OH [72]. As a result, the cooperative, bimetallic
pathway is not suggested to take place to a significant extent (Figure 18, red pathway)
[72], and the HKR reaction is suggested to be catalyzed primarily via a less selective,
monometallic pathway (Figure 18, blue pathway) [73]. Based on the above mechanis-
tic picture, it has been demonstrated that with a 1:1 ratio of Co(III)-salen-OH and
Co(III)-salen-SbF6, the fastest rates for the HKR occur, with the rapid formation of
the bimetallic transition state, allowing the enantioselective, bimetallic pathway to
dominate [72, 73].
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2.1.3 Origin of the high selectivity of Co(III)-salen-catalyzed HKR
As mentioned previously, the salen catalysts used for HKR are typically enantiopure,
which is required to successfully produce a highly enantiopure product. However,
Nielsen et al. suggested that each epoxide enantiomer bound to Co(III)-salen-X with
the same affinity (KE:matchedepoxide/KE:mismatchedepoxide = 1.0 ± 0.2 M−1) [72]. This
suggests that the binding of an epoxide to Co(III)-salen-X is not a strongly enan-
tiodiscriminating step, and thus, they concluded that the high enantioselectivity of
the HKR is predominantly due to the selective reaction resulting from the nucleophilic
Co(III)-salen-OH attacking one of the Co(III)-salen-X-epoxide complexes [72]. This
is consistent with the suggestion that the monometallic pathway (Figure 18, blue
pathway) [73] is less enantioselective (31% ee at 36% conversion, Table 2 [73]) than
the cooperative pathway (59% ee at 36% conversion, Table 2 [73]) (Figure 18, blue +
red pathway) [72, 73], although the still moderate enantioselectivity achieved using
only non-coordinating counter-ions suggests that (i) there is some selectivity asso-
ciated with epoxide binding or (ii) the bimetallic pathway still operates when only
trace amounts of the Co(III)-salen-OH species are produced [72].
Table 2: Catalyst selectivity as a result of the bimetallic or monometallic catalytic




1. X = Cl















Entry Catalyst Reaction time (h) Epoxide conversion (%) Epoxide ee (%) Catalytic pathway
1 1 0.5 36 59 Bimetallic
2 2 4 36 31 Monometallic
Based on these findings, it might be inferred that the chirality of the Co(III)-
salen-X (X = non-nucleophilic counter-ion) is less important or even unimportant in
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determining the enantioselectivity of the HKR reaction. To probe this hypothesis,
the HKR of epoxides was evaluated using salen complexes constructed from a variety
of counter-ions (Cl−, OH−, SbF6
−, and −OAc) using both enantiopure and racemic
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Figure 20: Co(III)-salen pre-catalysts used in this work, built from enantiopure (1,2)
and racemic (3,4) ligands [72].
If each complex is stable under the reaction conditions, a catalyst containing a
50:50 mix of (R,R)-Co(III)-salen-OH and (±)-trans-Co(III)-salen-SbF6 might pro-
vide good activity and enantioselectivity for the HKR of epoxides that is comparable
to a catalyst containing a 50:50 mix of (R,R)-Co(III)-salen-OH and (R,R)-Co(III)-
salen-SbF6. This 50% decrease in use of the more expensive chiral ligand [80] could
provide significant practical advantages for Co(III)-salen-catalyzed HKR reactions.
To this end, mixed (R,R)-Co(III)-salen-OH and (±)-trans-Co(III)-salen-SbF6 cata-
lyst systems are explored here for the HKR of racemic epichlorohydrin. This approach
is not found to yield highly enantioselective catalysis, and the causes for the reduced
selectivity are enumerated in this study, providing further insights into the nature of




Reagents were purchased from commercial vendors and used as received unless oth-
erwise stated. All solid starting materials were dried under high vacuum before use,
and anhydrous solvents were obtained either from a solvent purification system or
from a bottle sealed under nitrogen (from commercial vendors). Prior to use, divinyl-
benzene (DVB) was washed with 5% NaOH (2x) and deionized water (2x) to remove
the polymerization inhibitors, and then it was dried with anhydrous MgSO4.
2.2.2 Instrumentation
1H NMR spectra were obtained using a Varian Mercury spectrometer (400 MHz); the
chemical shifts were expressed in ppm and are referenced to the corresponding residual
nuclei in the deuterated solvents. FT-IR spectra were obtained using a Bruker Vertex
80v (Ram II) by dispersing the samples in a KBr pellet. Elemental analyses (EA)
of the samples were performed by Columbia Analytical Services, Tuscon Laboratory
(Tuscon, AZ, USA). The conversion of racemic epichlorohydrin and the ee of (S )-
epichlorohydrin were determined using a Shimadzu 17A GC equipped with an FID
and Chiraldex γ-TA column (40 m x 25 mm x 0.25 µm). Either para-dichlorobenzene
or mesitylene was used as an internal standard.
2.2.3 Catalyst preparation
2.2.3.1 Synthesis of (R,R)- and (±)-trans-Co(III)-salen-Cl (1 and 3, respec-
tively)
Catalysts 1 and 3 were prepared according to previously published procedures, and
the characterization data matched the data previously reported [72].
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2.2.3.2 Synthesis of (R,R)- and (±)-trans-Co(III)-salen-SbF6 (2 and 4, respec-
tively)
Catalysts 2 and 4 were prepared according to previously published procedures, and
the characterization data matched the data previously reported [72] [73].
2.2.3.3 Synthesis of polymer resin-supported (R,R)-Co(III)-salen-OAc (8)
Catalyst 8 was prepared according to previously published procedures, and the char-
acterization data matched the data previously reported [81, 82, 83].
2.2.4 Synthesis of styrene/DVB resin
Styrene/DVB resin was synthesized according to previously published procedures [82].
A two-neck round-bottom flask equipped with a stirbar and a reflux condenser was
purged with nitrogen. Then, 1 equivalent of styrene and 5 equivalents of DVB were
added to the flask, and the reaction mixture was heated under nitrogen for 36 h at
80◦C. After cooling to room temperature, the white solid was then washed several
times with methanol and dichloromethane. After filtration, the resin was allowed to
dry overnight under high vacuum.
2.2.5 HKR of racemic epichlorohydrin
A pear-shaped flask equipped with a stirbar was charged with the respective catalyst
at the appropriate loadings (0.25 or 0.5 mol%). The flask was then immersed in a
water bath to keep the reaction temperature constant. Next, 1 equivalent of racemic
epichlorohydrin was added to the flask, followed by the internal standard (mesitylene
or para-dichlorobenzene). After stirring briefly, 2.5 µL of the mixture was passed
through a silica plug and washed with diethyl ether prior to the catalytic reaction.
Deionized water (0.6 equivalents) was then added to initiate the reaction. For ho-
mogeneous catalytic studies, 2.5 µL samples were taken until 99% ee or a constant,
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maximum % ee was reached. For reactions using the polymer resin-supported cat-
alysts, 2.5 µL samples were taken for 4 h.1 Samples from all of the reactions were
passed through a plug of silica gel (to remove the catalyst) and washed with diethyl
ether prior to GC/FID analysis.
2.2.6 Catalyst recovery
Upon completion of the HKR reactions using the polymer resin-supported catalysts,
the reaction mixture was filtered through a fritted funnel to isolate the solid catalyst,
and this catalyst was washed with dichloromethane until the liquid filtrate became
clear and colorless. The solid catalyst was dried under high vacuum overnight and
then analyzed via EA and FT-IR. The recovered filtrate was concentrated under
reduced pressure (T < 60◦C) to recover the homogeneous catalyst from the reaction.
This catalyst was also dried overnight under high vacuum and analyzed via EA.
2.3 Results and Discussion
As noted above, previous work has suggested that only the (R,R)-Co(III)-salen-OH
complex generated from (R,R)-Co(III)-salen-X containing a nucleophilic counter-ion
plays a key role in the enantiodiscriminating step of HKR [72]. To this end, an array of
reactions was first explored to evaluate the ligand chirality and the role of the counter-
ion in the HKR of racemic epichlorohydrin (Tables 3 and 4, respectively). Specifically,
both the (±)-trans-salen and (R,R)-salen ligands were used in combination with
the non-nucleophilic SbF6
− counter-ion and the nucleophilic Cl− counter-ion, which
has been suggested to rapidly convert to the OH− counter-ion under the reaction
conditions [72] (Table 3).
1The time elapsed to determine that 99% ee of the HKR reaction with catalyst mix 2 + 8 was
reached.
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Table 3: HKRa of racemic epichlorohydrin evaluating ligand chirality and the role of
the counter-ion. Data from Ref. [84].
Entry Catalyst Total loading (mol%)
Overall initial
TOF (min1) Time at ≥99% ee (m)
Total conversion at
≥99% ee (%) k relb
1 1 0.25 1.78 240 52.1 >99
2 2 0.25 0.89 1740c (97%)d 71.6 8.2
3 1 + 2 (50:50 mix) 0.50 3.23 180 56.8 36.0
4 1 + 4 (50:50 mix) 0.50 2.73 180c (77%)d 69.3 4.3
5 2 + 3 (50:50 mix) 0.50 2.79 187.5c (82%)d 71.9 4.5
aHKRs were run with 1 equiv. (rac)-epichlorohydrin (782.1 µL, 10 mmol) and 0.6 equiv. water (108.1 µL, 6 mmol).
para-Dichlorobenzene (120.3 µL) was used as an internal standard.
bkrel (selectivity factor) is determined by the equation ln[(1-C)(1-ee)]/ln[(1-C)(1+ee)], where C = conversion and ee = enantiomeric excess[67].
cTime at which the %ee reaches a maximum.
dDenotes maximum %ee reached by the reaction.
2.3.1 HKR of racemic epichlorohydrin
The conversion of racemic epichlorohydrin and the resulting enantiomeric excess (ee)
of (S )-epichlorohydrin were monitored by GC/FID using a chiral capillary column.
The results are collected in Table 3. In the first entry, the use of (R,R)-Co(III)-salen-
Cl (1) at 0.25 mol% catalyst loading is demonstrated to be an active and selective
catalyst over one use, providing a high turnover frequency (TOF) and good enan-
tioselectivity of the unreacted epichlorohydrin, achieving 99% ee at 52.1% conversion
(perfect selectivity would give a conversion of 50%) [84]. Catalyst 1 gave an initial
TOF of 1.78 min−1 [84] and displayed a selectivity marked by a very high k rel
2 of >99.
By comparison, at the same catalyst loading, the (R,R)-Co(III)-salen-SbF6 catalyst
(2) gave a much lower initial rate (0.89 min−1) and was also less enantioselective, with
a k rel of 8.2 (Table 3, entry 2) [84]. These results are consistent with the reaction
pathways described above, with the catalyst in entry 1 rapidly proceeding down the
selective pathway shown in Figure 18 (red + blue pathway) [72] and the catalyst in
entry 2 being shuttled through the less selective blue pathway (Figure 18) [73]. In
entry 3, a 50:50 mixture of the two counter-ions on the enantiopure ligand (catalysts
1 and 2) was employed at 0.5 mol% catalyst loading. This combination also gave a
2See Table 1 for the definition of krel [67].
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selective catalyst and was the most active of all runs, as exemplified in the literature
[72, 73].
Next, reactions were run with a 50:50 mixture of enantiopure and racemic salen
ligand. First, in entry 4, the reactions resulting from the use of (R,R)-Co(III)-salen-
Cl (1) and (±)-trans-Co(III)-salen-SbF6 (4) are described. If the enantiospecificity
of the reaction was largely determined by the chirality of the complex with the nu-
cleophilic counter-ion, in this case complex 1, then this reaction should proceed with
identical selectivity as entry 1 in the absence of counter-ion exchange. However, as
shown in the table, this catalyst combination was less selective relative to the reac-
tions described in entries 1-3, suggesting that either the mechanistic hypothesis above
is incorrect or that other factors are important. In entry 5, catalysts 2 and 3 [(R,R)-
Co(III)-salen-SbF6 and (±)-trans-Co(III)-salen-Cl, respectively] were used, with the
opposite pairing of ligands and counter-ions as seen in the previous case (entry 4).
Based on the mechanistic hypothesis described above, this catalyst should be the
least selective of the combinations in the absence of counter-ion exchange. However,
as shown in Table 3, this catalyst combination (entry 5), while also unselective, gave
nearly identical results to entry 4. These last two runs, in combination, are consistent
with the occurrence of a rapid scrambling of counter-ions under the reaction condi-
tions, as such scrambling should produce the same average combination of catalysts
in both entries 4 and 5. If this scrambling were to occur, the above results would
then remain fully consistent with the overall mechanistic picture described in Figure
18 [72, 73, 74, 75] and remove the possibility of lowering the cost of the reactions by
using a combination of enantiopure and racemic ligands. Therefore, the counter-ion
exchange hypothesis was explored in more detail to support or refute this hypothesis.
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2.3.2 Co(III)-salen-X counter-ion exchange
One approach for determining whether the counter-ion exchange is present in a mixed
counter-ion Co(III)-salen system is to separate and isolate one Co(III)-salen-X species
from the other for direct characterization; this can best be explored by immobilizing
one of the Co(III)-salens on a support. Previously, Co(III)-salen-OTf complexes have
been immobilized on gold colloids [85], and the Jones and Weck groups have immo-
bilized metallosalens on silica [86], soluble polymers [81, 87], polymer resins [82, 86],
and oxide-supported polymer brushes [88]. (R,R)-Co-salen-OAc (8) was supported
on a polymer resin with a flexible ethylene glycol linker, as these salens have pre-
viously been used to give good catalytic rates and selectivities, as reported by the
Jones and Weck groups (Figure 21) [81, 82, 83]. This catalyst was combined with
(R,R)-Co(III)-salen-SbF6 as a soluble homogeneous catalyst (Figure 20, catalyst 2)
[73]. Catalysts 2 (Figure 20)[72] and 8 (Figure 21) [81, 82, 83] were prepared ac-
cording to previously published procedures [73, 81, 82, 83] and characterized by EA
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Figure 21: Scheme of the reaction pathways for the formation of the resin-supported
Co(II)- and Co(III)-salens for the HKR reactions [81, 82, 83].
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Table 4: Elemental analysis data from the catalysts used for HKRa evaluating the
counter-ion exchange. Data from Ref. [84].
Entry Catalyst C (wt.%) H (wt.%) N (wt.%) Sb (wt.%) Co (wt.%) mol Co/mol N mol Sb/mol Co
1 2, Fresh 48.63 6.19 3.04 12.92 6.11 0.48 1.02
2 7, Fresh 80.81 8.96 1.88 <0.04 3.23 0.50 <0.01
3 8, Fresh 78.31 7.52 1.89 <0.30 3.17 0.40 <0.05
4 8b 74.24 7.70 1.50 <0.20 2.74 0.43 <0.04
5 2 + 8c 68.38 6.90 1.39 1.39 2.58 0.45 0.26
6 Filtrate of 2 + 8 reactionc 33.81 5.81 0.19 0.31 0.25 0.32 0.60
7 2 + 7c 72.43 6.87 1.54 2.05 2.88 0.44 0.34
8 Filtrate of 2 + 7 reactionc 35.03 6.17 0.14 0.24 0.20 0.34 0.58
9 Styrene/DVB Resin,d Fresh 90.51 7.83 0.94 <0.03 <0.03 <0.01 N/A
10 2 + Styrene/DVB resinc 90.09 7.83 0.72 <0.08 <0.03 <0.01 N/A
11 Filtrate of 2 + styrene/DVB resin reactionc 37.22 5.69 0.54 2.11 1.12 0.49 0.91
aHKRs were run with 1 equiv. (rac)-epichlorohydrin and 0.6 equiv. water. Mesitylene was used as an internal standard.
bRecovered after one HKR cycle.
cSolid catalyst, 8, or Co(II)-salen-functionalized resin, 7, recovered from the catalyst mixes denoted above after one HKR cycle.
dBlank polymer resin composed of styrene crosslinked 1:5 with DVB.
HKR reactions were run with the combination of resin-supported (R,R)-Co(III)-
salen-OAc (8) and homogeneous (R,R)-Co(III)-salen-SbF6 (2), along with the ap-
propriate control reactions (Table 4, entries 1-4). Following the HKR, the resin-
supported salens were recovered via vacuum filtration for analysis via EA and FT-IR.
If counter-ion exchange occurred during the reactions, the spent supported catalysts
should exhibit an increased Sb/Co ratio, and an Sb-F stretch near 660 cm−1 should
be apparent in the FT-IR spectrum of the recovered solid, which was initially Sb-free
[89].
For the HKR reaction with a catalyst mix of 2 (Co(III)-salen-SbF6) and 8 (sup-
ported Co(III)-salen-OAc), the supported spent catalyst 8, when analyzed by EA,
had an Sb/Co ratio of 0.26 (Table 4, entry 5). Although the Sb/Co ratio ratio ob-
served for this catalyst mix is less than the Sb/Co ratio of fresh catalyst 2 that is
fully oxidized to Co(III)-SbF6 (1.02, Table 4, entry 1), it is greater than the Sb/Co
ratio of the fresh and spent catalyst 8, which has no SbF6
− counter-ion (<0.05 and
<0.04, Table 4, entries 3 and 4, respectively). This suggests that some of the SbF6
−
counter-ion from the homogeneous catalyst 2 has exchanged with the counter-ion
from the supported catalyst 8. To verify the presence of SbF6
− in the spent catalyst
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8, the solid was examined by FT-IR [84].
Figure 22: FT-IR spectra of the fresh (solid line) and spent resin-supported (R,R)-
Co(III)-salen-OAc (8) (after one HKR cycle, dotted line) and the recovered solid
catalyst 8 (dot-dashed line) from the HKR using homogeneous (R,R)-Co(III)-salen-
SbF6 + resin-supported (R,R)-Co(III)-salen-OAc (2 + 8). The appearance of the
Sb-F stretch at 661 cm−1 is indicative of the SbF6
− likely coordinating to the Co
center of the resin-supported (R,R)-Co(III)-salen. Data from Ref. [84].
A peak at 661 cm−1 associated with an Sb-F stretch (Figure 22, dot-dashed line)
clearly suggests the presence of SbF6
− in the spent solid 8, whereas both the fresh
and spent catalyst 8 from regular reactions without catalyst 2 do not have this peak
(Figure 22, solid and dotted lines, respectively). Analysis of the filtrate of the HKR
reaction using catalyst mix 2 and 8 (which includes homogeneous (R,R)-Co(III)-
salen-SbF6) gave an Sb/Co ratio of 0.60 (Table 4, entry 6), indicating that there is
a decrease in SbF6
− relative to the fresh catalyst 2 (Table 4, entry 1). Based on the
data presented in Table 4 and Figure 22, it can be concluded that there is a degree
of counter-ion exchange occurring, where SbF6
− is transferred from the homogeneous
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(R,R)-Co(III)-salen 2 to the resin-supported (R,R)-Co(III)-salen 8, which originally
included −OAc [84].
This exchange is further exemplified when an HKR reaction is run with the homo-
geneous (R,R)-Co(III)-salen-SbF6 and the resin-supported (R,R)-Co(II)-salen, which
is orange in color (catalyst mix 2 and 7, respectively). A brown solid catalyst was
recovered from this reaction, indicative of a Co(III)-salen species supported on the
resin. The Sb/Co ratio for this catalyst was 0.34 (Table 4, entry 7), which is greater
than the ratio that would be expected for catalyst 7, which has no counter-ion coordi-
nated to the Co center (<0.01, Table 4, entry 2). This suggests that either the SbF6
−
species is transferred onto the supported Co(II) species, converting it to Co(III)-SbF6,
or that the homogeneous Co(III)-salen-SbF6 species are trapped within the resin. In
this case, the spent resin material, 7, also shows an Sb-F stretch at 661 cm−1 in its
FT-IR spectrum (Figure 23, dotted line), whereas the spectrum of the fresh catalyst
7 does not show this peak (Figure 23, solid line). The light brown filtrate from the
HKR reaction using catalysts 2 and 7 gives an Sb/Co ratio of 0.58 (Table 4, entry
8), indicative of a partial SbF6
− transfer from the homogeneous (R,R)-Co(III)-salen
to the resin-supported (R,R)-Co(II)-salen [84].
To determine whether significant amounts of SbF6
− become trapped within the
polymer resin without reacting with a Co-salen center, HKR reactions were run using
catalyst 2 and a polymer resin composed of a 1:5 cross linked styrene/DVB, which
does not include any salen species. In evaluating the EA data, the Sb content in
both the fresh and spent styrene/DVB resins were found to be negligible (Table 4,
entries 9 and 10). Moreover, there was no Sb-F stretch observed at 661 cm−1 in the
FT-IR spectra (Figure 23, dot-dashed line). In addition, the dark green filtrate of
the HKR reaction with the salen-free styrene resin and 2 had a Co/N ratio of 0.49
and an Sb/Co ratio of 0.91 (Table 4, entry 11), indicating that nearly all of complex
2 was recovered (Table 4, entry 1). Because an increase in the Sb/Co ratio and
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Figure 23: FT-IR spectra of the fresh (solid line) resin-supported (R,R)-Co(II)-
salen (7), the recovered solid catalyst (dotted line) from the HKR reaction using
homogeneous (R,R)-Co(III)-salen-SbF6 + resin-supported (R,R)-Co(II)-salen (2 +
7), and the recovered solid catalyst from the HKR reaction using homogeneous (R,R)-
Co(III)-salen-SbF6 (2) + styrene/DVB resin (dot-dashed line). The appearance of
an Sb-F stretch at 661 cm−1 is indicative of the SbF6
− likely coordinating to the Co
center of the resin-supported (R,R)-Co-salen. Data from Ref. [84].
the presence of the Sb-F stretch are observed in the spent catalysts upon exposure
to catalyst 2 and minimal to no amount of catalyst 2 becomes trapped within the
salen-free polymer resin, it can be concluded that the Sb species found in the spent
catalysts from entries 5 and 7 of Table 4 are indicative of the prevalence of a counter-
ion exchange occurring between SbF−6 and
−OAc. Thus, the similar reactivity seen in
Table 3, entries 4 and 5, demonstrates that rapid counter-ion exchange occurs between
the Co(III)-salen species during catalysis, and therefore, mixed chiral-racemic ligand
systems cannot be used to reduce the cost of HKR reactions [84]. It should further
be noted that the counter-ion scrambling is consistent with the mechanism of Nielsen
et al., which describes the Lewis acidic Co(III)-salen-X activating the epoxide, while
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the nucleophile-delivering Co(III)-salen-OH selectively attacks this activated epoxide
[79].
2.4 Conclusions
The potential of combining chiral and racemic ligands in the enantioselective HKR of
epoxides based on the mechanistic hypotheses of Nielsen et al. was explored [72].
Based on the currently accepted mechanism, high activity and enantioselectivity
might be achieved in reactions catalyzed using 50% enantiopure ligand with a counter-
ion designed to make the salen complex a nucleophile-delivering complex (e.g., OH−)
and 50% racemic ligand with a counter-ion designed to make the salen complex a
Lewis acidic, electrophilic complex (e.g., SbF6
−). In this work, it was shown that
such experiments do not lead to highly selective catalysis due to counter-ion scram-
bling between the Co centers. The counter-ion scrambling hypothesis was supported
by control experiments using a polymer-supported Co-salen species and the associ-
ated kinetic evidence, FT-IR spectra, and EA results. This study also showed that
the oxidation of a Co(II) species on a polymer support can be promoted via contact
with a homogeneous Co(III) species, which suggests a method for catalyst regener-
ation after deactivation by counter-ion loss, a there is a need for supported catalyst
regeneration, as it is currently a drawback in commercial-scale catalysis [83, 90].
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PROGRESS TOWARD THE SYNTHESIS OF
CALLOPHYCOLIDE A, AN ANTIMALARIAL BENZENE
DITERPENOID
Malaria is an extremely serious infectious disease caused by the parasite Plasmodium
falciparum, the deadliest malaria-carrying parasite to humans [5, 6]. A total of 300-
500 million cases of malaria are reported annually, with 1-2 million of these cases
being fatal [3]. Historically, natural products, along with their synthetic derivatives,


















IC50 = 7 nM
Figure 24: Former and current natural products used to treat malaria [4].
The cinchona tree bark component quinine (Figure 24) [4] was used as an an-
timalarial treatment for centuries until its synthetic derivative, chloroquine (Figure
24) [4], replaced it in the 1940s [20]. Chloroquine was the treatment of choice for
nearly 50 years until resistance to the drug emerged [91, 92]. Artemisinin (Figure
40
24) [4], which is isolated from the plant Artemisia annua, subsequently emerged as a
treatment for malaria and is currently the most fast-acting, potent drug available to
date, with an IC50 > 7 nM [38, 39]. Unfortunately, malaria strains that are resistant
to artemisinin have been reported [93, 94]. With artemisinin resistance on the rise,
there is an urgent need to pursue alternative antimalarial treatments.
3.1 Introduction
In 2005, Kubanek et al. discovered a novel class of macrolides from Callophycus serra-
tus [50]. Characterization of these macrolides using X-ray crystallography, NMR, and
MS revealed that each macrolide consisted of a diterpene-benzoate structure (Figure
25) [50, 51, 52, 53, 54]. It was later determined via an adapted SYBR Green parasite
proliferation assay [52, 95, 96] that bromophycolides A, D, E, H, and M expressed
potent activity against P. falciparum, with IC50 values ranging from 0.3 to 0.9 µM
[52]. All of the above compounds contain a macrolide motif, as depicted in Figure
25 [50, 51, 52, 53, 54]. In contrast, other natural products isolated from C. serratus
lacking the macrolide motif, such as the callophycoic acids, callophycols, and bromo-
phycoic acids, are not as potent as the bromophycolides against P. falciparum, with
IC50 values ranging from 8.7 to > 100 µM; therefore, with respect to antimalarial
activity, the lactone macrocycle is a critical component of the structure-activity re-
lationship (SAR) between the aforementioned natural products and their activities
against P. falciparum (Figure 26) [55, 54, 56, 52].
Now that multiple antimalarial benzoate-diterpenes and their SARs have been
identified, the next step is to increase the likelihood of these antimalarials becoming
APIs. In addition to being a potent antimalarial agent, bromophycolide A was found
in the greatest abundance by Kubanek et al. [50]. Therefore, bromophycolide A
(Figure 27) [50, 52, 51] is the most practical starting point concerning key antimalarial
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IC50 = 2.1 µΜ
Bromophycolide H; R = Br (R)
IC50 = 0.9 µΜ
Bromophycolide I; R = OH (S)
IC50 = 2.5 µΜ
Figure 25: Benzoate diterpenoids isolated from C. serratus [50, 51, 52, 53, 54].
as with the other aforementioned macrolides, that could decrease their probability
of becoming commercially available drugs. Primarily, the method for isolating these
natural products involves several liquid-liquid partitioning steps followed by normal
and/or reversed phase HPLC fractionation [52, 51, 54, 53] to obtain, for example,
4 mg of pure natural product [51]. Despite the fact that bromophycolide A is the
most abundant natural product isolated from C. serratus [5], obtaining large-scale
quantities of this material via extraction is not practical or realistic, as multiple grams
of bromophycolide A are needed for further studies regarding its antimalarial activity
[97]. Although efforts toward a concise, seven-step approach have been made in
synthesizing the bromophycolide D skeleta [57], there is currently no known divergent
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Callophycol A; X1=Br X2=Cl
Callophycol B; X1=Cl, X2=Br
H
Figure 26: Diterpene-benzoic acids and diterpene phenols isolated from C. serratus
[55, 56].
A practical approach toward the synthesis of bromophycolide A is to first syn-
thesize alternative diterpene-benzoates, such as callophycolide A (Figure 27) [50, 54].
Although callophycolide A (IC50 of 5.2 µM) [54] is not as potent as bromophycolide A,
it was shown to inhibit bacterial growth (IC50 of 9.1 µM for both VREF and MRSA),
and it exhibits moderate anticancer activity (mean IC50 of 18 µM) [54]. Most impor-
tantly, it exhibits activity against P. falciparum (IC50 of 5.2 µM) [54]. Similar to the
bromophycolides, it consists of a 15-membered macrolide. The macrolide structure of
callophycolide A is simple, with only two stereocenters and no bromine atoms present















Figure 27: Structural comparison of the macrolides bromo- and callophycolide A
[50, 54].
serve as a template for obtaining more potent derivatives. In addition, when Stout
et al. isolated and characterized callophycolide A, they were able to only confirm the
absolute configuration of C-14 as S (Figure 27) [50, 54]. If a total synthesis can be
established for callophycolide A, the remaining three stereoisomers can also be synthe-
sized and tested for biological activity, thus confirming absolute configurations and,
therefore, the exact meroditerpene isolated previously [54]. Herein, efforts toward a
divergent total synthesis of callophycolide A (1) are sought that incorporate inexpen-
sive, commercially available starting materials, such as methyl 4-hydroxybenzoate (4)
and geraniol (7), and that utilize known chemistry, including copper-mediated aryl
allylation, hydrolytic kinetic resolution (HKR), base-promoted epoxide ring-opening,
and the Steglich esterification. If the synthesis is successful, then it can serve as
a template for the synthesis of more potent, as well as more structurally complex,
antimalarials.
3.2 Retrosynthetic analysis of compound (1)
Evaluating the retrosynthesis shown in Figure 28, the target molecule 1 can be syn-
thesized via a Steglich esterification of compound 28. Alkylation product 28 can be
formed through a base-promoted epoxide ring-opening reaction using (2S,3R)-MOM-
epoxylinalool (21, formed via Co-salen-catalyzed HKR) and phenylsulfonylaliphatic
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arene 18. Compound 18 can be synthesized through a copper-mediated aryl ally-







































Figure 28: Retrosynthetic analysis of callophycolide A (1).
3.3 Results and Discussion
3.3.1 Copper-mediated aryl allylation
Compound 6 was formed in two steps from 36 g of commercially available methyl
4-hydroxybenzoate (4, Figure 29), followed by MOM-protection of methyl 4-hydroxy-
3-iodobenzoate (5) [98, 99]. 8-phenylsulfonylgeraniol (12) can be synthesized in five
steps beginning with the commercially available geraniol (7, Figure 30) (note that
allylic bromides, such as 8-phenylsulfonylgeranyl bromide (13) do not have a long
shelf-life and are thus made on an as-needed basis) [98, 100, 60, 101, 102, 103, 104].
With compounds 6 and 13 in hand, efforts can be made toward the endgame
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Figure 30: Scheme of the formation of 8-phenylsulfonylgeranyl bromide 13 from
geraniol [98, 100, 60, 101, 102, 103, 104].
18. Efforts regarding the use of compound 6 and geranyl bromide (14) for copper-
mediated aryl allylation [100] resulted in the formation of the desired aliphatic arene
(15) in 44% yield (Figure 31) [100, 102, 103].
Allylic oxidation of 15 (to form 16), followed by allylic bromination (forming 17)
and then sulfonation at the allylic position resulted in the formation of compound 18
[100, 102, 103]. However, due to the low yields, primarily due to the allylic oxidation
step (forming 16 in 24% yield), the coupling of MOM-Ar-I (6) and 8-phenylsulfonyl
bromide (13) was proposed, as the route to form 13 (Figure 30) [98, 100, 60, 101,
102, 103, 104] allows for the allylic oxidation step to occur earlier in the synthetic
















































Figure 31: Scheme of the initial proposed synthesis for phenylsulfonylaliphatic arene
18 [100, 102, 103].
overall yield of the target molecule.
3.3.2 Base-promoted epoxide ring-opening (ERO)
Toward synthesizing compound 28, (2S,3R)-MOM-epoxylinalool (21) was initially
synthesized via the Sharpless asymmetric epoxidation of commercially available (R)-
linalool (19), followed by MOM protection of (2S,3R)-epoxylinalool (20) (Figure 32)
[105, 99, 106, 107].
Due to the trace quantities obtained from the synthesis of 20, an alternative route
to synthesizing compound 21 was sought. As mentioned in the previous chapter, HKR
is a method for synthesizing enantiopure terminal epoxides, which can be used as
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Figure 32: Scheme of the synthesis of (2S,3R)-MOM-epoxylinalool (21) [105, 99,
106, 107].
chiral terminal epoxide 21, Singh et al. utilized (R,R)-Co(III)-salen-OAc-catalyzed
(Figure 32) [105, 99, 106, 107] HKR for the formation of (S )-2-(oxiran-2-yl)propan-2-
ol, a 2,3-epoxyalcohol, in 30% yield and 96% ee [107]. Thus, it was proposed that HKR
could be used to produce the compound 20, also a 2,3-epoxyalcohol, with significantly
greater yields than with using the Sharpless asymmetric epoxidation. Therefore, the
alternative synthesis for 21 was to involve epoxidation of 19 to form racemic 22,
followed by HKR of 22 to form 20, and then MOM protection would provide 21
(Figure 32) [105, 99, 106, 107]. Prior to synthesizing chiral compound 21, a model
system for the synthesis of compound 26 was investigated to optimize the ERO, as
well as the desulfonylation (to form 27) using ((2-methylallyl)sulfonyl)benzene (24)































Figure 33: Scheme of the ERO model system, which should result in the formation
of compound 27 [108, 109, 110].
Compound 24 was synthesized in moderate yield from commercially available 3-
chloro-2-methylpropene (23). Then, the ERO reaction was investigated; the reaction
conditions are listed in Table 5 [109, 110]. In testing various reaction conditions, it
was determined that the reaction conditions [109, 110] displayed in entries 3 and 4
of Table 5 afforded product. However, the yields were low (24%), and the products
isolated were determined to be impure by both 1H NMR and ESI-MS. Despite all
precautionary measures to prevent exposure of the reaction to air and moisture, reac-
tion yields did not improve. Therefore, further investigations are needed to optimize
alkylation via base-promoted ERO to continue to determine the synthetic routes for
callophycolide A.
3.4 Conclusions
Routes toward a divergent, modular, multi-gram scalable total synthesis of callo-
phycolide A were sought in an effort to confirm the absolute configuration of the
compound previously reported [54], perform a thorough determination of biological
49
Table 5: Reaction conditions for the ERO model system for the synthesis of callo-










Entry equiv. 24 Conc. 24 in THF (M) equiv. 25 equiv. nBuLi Conc. THF (M) Reaction time and temperature Yield (%)
1 1 neat 1 2.02 0.25 0◦C, 1h, then -78◦C-RT, 12h No reaction
2 1 neat 1 1 0.25 0◦C, 1h, then -78◦C-RT, 12h No reaction
3 1.21 0.16 1 1.3 0.45 -78◦C, 4h 24 (impure)
4 1 neat 1 1 0.25 -78◦C, 10m, then RT, O/N 24 (impure)
activity, and determine synthetic steps, as well as intermediates that could be used
to synthesize more potent antimalarials isolated from C. serratus, such as bromo-
phycolide A. While progress toward this goal was achieved, a thorough, extensive
investigation of the optimal conditions for the base-promoted ERO is essential to the
success of the total synthesis of callophycolide A. Therefore, our attention was turned
toward the total syntheses of alternative diterpenes isolated from C. serratus and will
later return to optimization of the ERO. Once this step is successful, the focus can
be returned to applying HKR to form the enantiopure epoxide 20; once capped with
MOM (forming 21), it can be utilized for ERO to form compound 28.
3.5 Experimental
3.5.1 General
Reagents were purchased from commercial vendors and were used as received unless
otherwise stated. All starting materials were dried under vacuum prior to use. An-
hydrous DCM was distilled from CaH2, and anhydrous THF was distilled from Na
and benzophenone. nBuLi (2.5 M in hexanes) was purchased from Sigma-Aldrich
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(St. Louis, MO USA) and titrated against N -(3-benzylphenyl)pivalamide (recrys-
tallized in hexanes) prior to use. Grignard reagents were titrated against (E )-2-((2-
phenylhydrazono)methyl)phenol. All glassware was flame dried and placed under a
nitrogen atmosphere prior to use. Purification via flash chromatography was per-
formed using silica gel from Dynamic Adsorbents (32-65 µm) and technical grade
eluents. Thin-layer chromatography (TLC) was conducted using EMD silica gel 60
F254 glass-backed plates. Plate visualization was accomplished using UV light and/or
iodine staining. 1H NMR spectra were obtained using either a Varian Mercury Vx
spectrometer (300 or 400 MHz) or a Bruker AVII (400 or 500 MHz) spectrometer;
the chemical shifts were expressed in ppm and are referenced to the corresponding
residual nuclei in the deuterated solvents. ESI-MS and accurate mass was performed
using a ThermoFisher Scientific LTQ Orbitrap XL ETD.
3.5.2 Synthesis of compounds to construct callophycolide A
Compounds 5, 6, 8-12, 20-22 and 24 were prepared according to previously pub-
lished procedures, and the characterization data matched the data previously reported
[98, 100, 60, 101, 102, 103, 104, 105, 99, 106, 107, 108].
3.5.3 Synthesis of methyl (E)-3-(3,7-dimethylocta-2,6-dien-1-yl)-4-
(methoxymethoxy)benzoate (15)
To a solution of compound 6 (4 g, 12.4 mmol) in anhydrous THF (62 mL) was added
iPrMgCl (12.6 mL, 1.48 M in THF ) dropwise at -15◦C. The reaction was then allowed
to stir for 1 h. Li2CuCl4 (40.9 mL, 0.1M in THF ) was then added dropwise, and
the reaction was stirred for 30 min. A solution of geranyl bromide (14) (2.4 mL, 12.3
mmol) in anhydrous THF was added over a period of 30 min, and the reaction was
allowed to stir for an additional 1.5 h. The reaction was then quenched with saturated
aqueous NH4Cl and was allowed to stir until the reaction mixture turned blue. The
mixture was then extracted with ether (3X), and the organic layer was washed with
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brine, dried using anhydrous Na2SO4, and concentrated under reduced pressure [100].
Purification (silica gel and 0-1-2% EtOAc:hexanes) afforded the aliphatic arene 15 as
a clear, colorless oil in 44% yield. 1H NMR (CDCl3, 400 MHz) δ 7.87-7.83 (m, 2H),
δ 7.11-7.06 (d, 1H), δ 5.32-5.29 (tq, 1H), δ 5.26 (s, 2H), δ 5.12-5.08 (tq, 1H), δ 3.87
(s, 3H), δ 3.47 (s, 3H), δ 3.37-3.35 (d, 2H) δ 2.14-2.03 (m, 4H), δ 1.72 (s, 3H), δ 1.66
(s, 3H), δ 1.59 (s, 3H).
3.5.4 Synthesis of methyl 3-((2E,6E)-8-hydroxy-3,7-dimethylocta-2,6-dien-
1-yl)-4-(methoxymethoxy)benzoate (16)
To a round-bottom flask equipped with a stirbar was added SeO2 (5.5 mg, 0.05 mmol),
salicylic acid (15.2 mg, 0.11 mmol), TBHP (0.6 mL, 5.5M in nonane), and anhydrous
DCM (1.25 mL). The above compounds were allowed to stir for 40 min at room
temperature. The reaction mixture was then cooled to 0◦C; a solution of 15 (332.1
mg, 1.0 mmol) in anhydrous DCM (0.72 mL) was added in one shot, and the reaction
mixture was allowed to stir at 0◦C for 5 h. The mixture was then washed with
saturated aqueous NaHCO3, dried using anhydrous Na2SO4, and concentrated under
reduced pressure. The crude oil was then dissolved in a 4% MeOH:THF solution
and cooled to 0◦C. NaBH4 was added in portions, and the reaction mixture was
allowed to stir at 0◦C for 1 h before being quenched with ice-cold saturated aqueous
NH4Cl. After warming to room temperature, the mixture was extracted with ether
(3X), and the organic layer was washed with brine, dried using anhydrous Na2SO4,
and concentrated under reduced pressure [102]. Purification (silica gel and 2-5-7-10-
15-20% EtOAc:hexanes) provided 16 in 24% yield. 1H NMR (CDCl3, 300 MHz) δ
7.88-7.82 (m, 2H), δ 7.09-7.05 (d, 1H), δ 5.45-5.38 (tm, 1H), δ 5.37-2.59 (tm, 1H),
δ 5.27 (s, 2H), δ 3.98 (s, 2H), δ 3.88 (s, 3H), δ 3.48 (s, 3H), δ 3.39-3.34 (d, 2H) δ
2.24-2.06 (m, 4H), δ 1.71 (s, 3H), δ 1.65 (s, 3H).
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3.5.5 Synthesis of methyl 3-((2E,6E)-8-bromo-3,7-dimethylocta-2,6-dien-
1-yl)-4-(methoxymethoxy)benzoate (17)
In a round-bottom flask equipped with a stirbar, the hydroxyaliphatic arene (16)
(79.6 mg, 0.23 mmol) was dissolved in anhydrous ether (0.71 mL) and cooled to 0◦C.
PBr3 was added dropwise (0.01 mL, 0.091 mmol), and the reaction was stirred for 2
h in the dark. After warming to room temperature, the reaction mixture was poured
slowly into saturated aqueous NaHCO3 and then washed with saturated aqueous
NaHCO3, dried using anhydrous MgSO4, concentrated under reduced pressure, dried
under vacuum and carried forward to the next step without further purification [100].
3.5.6 Synthesis of methyl 3-((2E,6E)-3,7-dimethyl-8-(phenylsulfonyl)octa-
2,6-dien-1-yl)-4-(methoxymethoxy)benzoate (phenylsulfonylaliphatic
arene, (18))
A solution of bromoaliphatic arene (17) (14.2 mg, 0.035 mmol) in anhydrous DMF
(0.07 mL) was added to NaSO2Ph (5.7 mg, 0.035 mmol) at room temperature, and
then the solution was stirred for 16 h at room temperature. The organic compounds
were extracted with EtOAc (2X); the organic layer was then washed with H2O and
brine, dried over anhydrous MgSO4, and concentrated under reduced pressure [103]
to afford the crude compound 18 in 88% yield (over 2 steps).
3.5.7 Synthesis of 4-methyl-1-phenyl-3-(phenylsulfonyl)pent-4-en-1-ol (26)
3.5.7.1 Method A
Compound 24 (198.0 mg, 1.0 mmol) was dissolved in anhydrous THF (6.3 mL) and
cooled to -78◦C. nBuLi (0.46 mL, 2.35 M in hexanes) was added dropwise, and the
reaction was allowed to stir for 2.5 h. A solution of racemic styrene oxide 25 (0.1
mL, 0.83 mmol) in anhydrous THF (1.8 mL) was added, and the reaction was al-
lowed to stir for an additional 1.5 h. The reaction was then quenched with a 1:1
mixture of MeOH:ether. After warming to room temperature, the reaction mixture
was extracted with ether (3X), and then the organic layer was washed with brine,
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dried using anhydrous Na2SO4, and concentrated under reduced pressure [110]. Pu-
rification (silica gel and 10-15-20% EtOAc:hexanes) afforded impure compound 26 as
a clear, colorless oil in 24% yield. 1H NMR (CDCl3, 400 MHz) δ 7.94-7.76 (m, 2H) δ
7.66-7.60 (m, 1H), δ 7.56-7.49 (m, 2H), δ 7.38-7.27 (m, 5H), δ 5.15 (s, 1H), δ 4.87 (s,
1H), δ 4.64-4.60 (dd, 1H), δ 4.09-4.04 (dd, 1H) δ 2.57-2.43 (m, 1H), δ 2.23-2.09 (m,
1H), δ 2.05 (s, 1H), δ 1.77 (s, 3H). HRMS (ESI) [M + Na]+ Calc for C18H20O3SNa,
339.1025, found 339.1023.
3.5.7.2 Method B
Compound 24 (167.3 mg, 0.83 mmol) was dissolved in anhydrous THF (3.3 mL) and
cooled to -78◦C. nBuLi (0.31 mL, 2.71 M in hexanes) was added dropwise, and the
reaction was allowed to stir for 10 min. Racemic styrene oxide 25 (0.1 mL, 0.83
mmol) was added, and the reaction was allowed warm to room temperature and stir
overnight. The reaction was then quenched with a 1:1 mixture of MeOH:ether. After
warming to room temperature, the reaction mixture was extracted with ether (3X),
and then the organic layer was washed with brine, dried using anhydrous Na2SO4, and
concentrated under reduced pressure [110]. Purification (silica gel and 0-0.5-1-2-5-7%
MeOH:DCM) afforded impure compound 26 as a clear, colorless oil in 24% yield.
1H NMR (CDCl3, 400 MHz) δ 7.93-7.76 (m, 2H) δ 7.66-7.60 (m, 1H), δ 7.57-7.48
(m, 2H), δ 7.38-7.27 (m, 5H), δ 5.15 (s, 1H), δ 4.87 (s, 1H), δ 4.64-4.59 (dd, 1H), δ
4.09-4.03 (dd, 1H) δ 2.58-2.42 (m, 1H), δ 2.25-2.14 (m, 1H), δ 2.05 (s, 1H), δ 1.77 (s,
3H).
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PROGRESS TOWARD THE SYNTHESES OF
CALLOPHYCOIC ACIDS G AND H, ANTIBACTERIAL
DITERPENE-BENZOIC ACIDS
4.1 Introduction
Callophycoic acids are diterpene-benzoic acids that were also isolated from C. serra-
tus, a Fijian red macroalgae (Figure 34) [55, 56]. These compounds were characterized
via X-ray crystallography, MS, and NMR by Lane et al. and are the first examples of
diterpene-benzoic acids observed in macroalgae [55]. In addition, they display modest
antibacterial activity, namely, callophycoic acids G and H (IC50 for callophycoic acid
G = 31.9 µM against S. aureus ; 63.9 µM against E. faecium; for callophycoic acid H
= 27.4 µM against both S. aureus and E. faecium >10-63.9 µM) [55].
Structurally, although all callophycoic acids share the benzoic acid moiety, G and
H significantly differ in that they do not contain a fused tricyclic diterpene-benzoic
acid (Figure 34, in red) [55]. Instead, callophycoic acids G and H consist of a trans-
decalin moiety (Figure 34, in blue) [55]. With regard to the terpene head, callophycoic
acids G and H also differ from callophycoic acids A-F in that G and H contain an
isoprene tail, whereas the other callophycoic acids consist of either a monoterpene
(A and B), a bromocyclohexanol (C and D), a methylenebromocyclohexane (E), or
a sesquiterpene (F) unit (Figure 34, in purple) [55]. However, callophycolides G and
H do consist of the same trans-decalin core as callophycols A and B (Figure 34, in
blue) [55]. Due to this common trans-decalin core, a divergent total synthesis can
be envisioned for callophycoic acids G and H and callophycols A and B. Using the
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Figure 34: Structural comparisons of callophycoic acids and callophycols isolated
from C. serratus [55, 56].
would lead to functionalization to introduce the appropriate aryl groups for all four
metabolites, as well as to introduce the trisubstituted olefin (callophycoic acids G
and H) or vicinal dihalide (callophycols A and B) moieties, this synthetic approach
is modular in nature (Figure 35). As a result of these synthetic pathways, they
could also provide access to novel antibacterial agents, as bromophycoic acids A and
E also display modest activity against bacteria (IC50 = 1.6 µg/mL for Methicillin-
resistant Staphylococcus aureus (MRSA) for bromophycoic acid A; 1.6 µg/mL for
Vancomycin-resistant Enterococcus faecium (VREF)) in addition to accessing other
compounds that display modest activity against malaria, such as callophycols A and
56
B and bromophycoic acid D (IC50 = 35.7 µM, 40.4 µM, and 8.7 µM, respectively)
[55, 56]. Herein, postulated pathways to synthesize callophycoic acids G and H and
callophycols A and B are presented here, taking advantage of accessing a common
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Figure 35: Depiction of the common trans-decalin core to access callophycoic acids
G and H and callophycols A and B.
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4.2 Retrosynthetic analyses of callophycoic acids G (2) and
H (3)
A retrosynthetic route to callophycoic acids G (2) and H (3), is shown in Fig-
ure 36. These target molecules can be synthesized via a Wittig reaction between
triphenyl(propan-2-ylidene)-λ5-phosphane and either aldehyde 41 or 42. Aldehyde
41 or 42 can be formed by a cross-coupling reaction of arene 7 or 10, respectively, to
compound 40. Compound 40, which is a common intermediate to access callophycols
A and B, can be synthesized through a bromonium-induced cation-pi cyclization of
compound 39. Compound 39 can be formed by an oxidative cleavage reaction of
epoxide 27, which is formed via a bromohydrin reaction of geranylgeranyl acetate
(25), followed by epoxidation. Finally, geranylgeranyl acetate can be formed via
the Pd-catalyzed isomerization of commercially available, inexpensive geranyllinalool
(23).
4.3 Results and Discussion
4.3.1 Synthesis of 3-bromo-4-(methoxymethoxy)benzoic acid (7) and 3,5-
dibromo-4-(methoxymethoxy)benzoic acid (10)
Compound 7 was formed in three steps using the commercially available 3-bromo-4-
hydroxybenzoic acid 4 (Figure 37) [111, 112, 113]. Specifically, transesterification of
4 formed compound 5; MOM protection of the phenol group formed compound 6, all
in high yields. Saponification of 6 formed 7 in moderate yield (42%) [111, 112, 113],
which will later be used in the endgame of the synthesis of callophycoic acid G.
Similarly, compound 10 can also be formed via bromination of compound 5, followed
by protection of the phenol (to form 9) and then saponification to give compound 10,
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Figure 36: Initial retrosynthetic analysis of callophycoic acids G (2) and H (3).
4.3.2 Synthesis of (2E,6E,10E)-14-((tert-butyldiphenylsilyl)oxy)-3,7,11-
trimethyltetradeca-2,6,10-trien-1-yl acetate (54): the precursor to
the trans-decalin core
Initial attempts at forming the precursor to the trans-decalin core of callophycoic
acids G and H and callophycols A and B involved the use of dioxolane 39 (Figure
38) [114, 115, 59, 116, 117, 118]. Attempts to form compound 39 using a Horner-
Wadsworth-Emmons reaction involving phosphonate 13 and aldehyde 14 (synthesized
in three steps from commercially available farnesyl acetate (19) (Figure 39) [119, 120]
were investigated. Many reaction conditions were examined using various bases, such
as nBuLi, LDA, NaOH, NaOEt, and NaNH2; the use of nBuLi with additive appeared
















































Figure 37: Synthesis of 3-bromo-4-(methoxymethoxy)benzoic acid 7 and 3,5-
dibromo-4-(methoxymethoxy)benzoic acid (10) [111, 112, 113].
result of nucleophilic addition to the carbonyl groups on the molecule.
After evaluating a simpler model system using phosphonate 13 and benzaldehyde
21, as shown in Figure 40 [121], it was concluded that the benzaldehyde was in-
deed undergoing nucleophilic addition via nBuLi (thus not forming compound 22);
therefore, other avenues were investigated toward obtaining compound 39.
Rather than synthesizing the farnesyl acetate trisnoraldehyde 14 and priming
it for nucleophilic attack to form the desired farnesyl derivative (dioxolane 39), a
more straightforward approach was proposed that initially involved starting with the
commercially available (2E,6E,10E )-geranylgeraniol. However, due to the cost of ger-
anylgeraniol ($519 per 1 g [122]), the less expensive geranyllinalool (23, $8.68 per 1
g [123]) was used as the starting material instead. Evaluating the forward synthesis
(Figure 41) [124, 125, 119, 126, 127, 128, 129], the hydroxyl group of commercially
available geranyllinalool (23) was protected with an acetyl group, thus forming ger-
anyllinalyl acetate (24) in moderate yield (67%) [124].
Pd-catalyzed isomerization of 24 produced geranylgeranyl acetate 25 in high yield
[124]. Subjecting compound 25 to N -bromosuccinimide (NBS) in aqueous solution
formed bromohydrin 26, which was then treated with 1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU) to form epoxide 27 in moderate yield (42% over two steps) [125, 119,




























































Figure 38: Synthesis of (2E,6E,10E )-13-(1,3-dioxolan-2-yl)-3,7,11-trimethyltrideca-
2,6,10-trien-1-yl acetate 18 [114, 115, 59, 116, 117, 118].
Aldehyde 28 was originally going to be protected with a dioxolane group (compound
39) prior to the cascade cyclization reaction (Figure 41) [124, 125, 119, 126, 127, 130,
59]. However, subjecting dioxolane 39 did not result in the formation of compound
40; instead, the BDSB activated the dioxolane, which resulted in deprotection to
give aldehyde 28 (Figure 42), as is reflected in the 1H NMR spectra. Therefore,
other protecting groups were sought that would be more stable under the reaction
conditions, such as a silyl group. Thus, reduction of aldehyde 28 (producing alcohol
29, 71% yield), followed by the protection of the alcohol, thus forming a TBDPS-
protected ether, gave compound 30 in high yield (79%) (Figure 43) [124, 125, 119,
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Figure 40: Model system for determination of the conditions for the Horner-
Wadsworth-Emmons step of the synthetic pathway [121].
4.3.3 Synthesis of (1R,4aS,5R,6R,8aR)-6-bromo-5-(3-((tert-
butyldiphenylsilyl)oxy)propyl)-5,8a-dimethyl-2-
methylenedecahydronaphthalene-1-carbaldehyde (32)
With compound 30 in hand, formation of the trans-decalin core was investigated. It
was proposed that callophycoic acids G and H, as well as callophycols A and B, most
likely underwent a sequence of hydride shifts, followed by addition and elimination
reactions, which are charasterictic of the biosynthesis of isoprenoids [131]. The afore-
mentioned series of reactions resulted in the halogenation of the compounds at their
electrophillic sites that can be obtained via vanadium haloperoxidase-based biosyn-
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Figure 41: Synthesis of ((1R,2S,4aS,5R,6R,8aR)-5-(2-(1,3-dioxolan-2-yl)ethyl)-6-
bromo-2-hydroxy-2,5,8a-trimethyldecahydronaphthalen-1-yl)methyl acetate (40) us-
ing dioxolane 39ald, which was synthesized from geranyllinalool (23)[124, 125, 119,
126, 127, 130, 59].
circumvent the issue of poor stereoselectivity observed using vanadium haloperoxi-
dases, bromodiethylsulfonium bromopentachloroantimonate(V) (BDSB), which has
been used in the formation of stereospecific cation-pi cascade cyclizations, will be
applied to the syntheses in the current study [59].
Specifically, the Snyder group had applied these cation-pi cascade cyclizations to
the total syntheses of (both racemic and structurally revised) peyssonol A [132, 133],
peyssonoic acid A [134], as well as a formal total synthesis of aplysin-20 [135, 136],
all of which include the same or similar trans-decalin core [59] as callophycoic acids






























Figure 43: Synthesis of the trans-decalin precursor (2E,6E,10E )-14-((tert-
butyldiphenylsilyl)oxy)-3,7,11-trimethyltetradeca-2,6,10-trien-1-yl acetate (30) [124,
125, 119, 126, 127, 128, 129].
Therefore, it was proposed that the trans-decalin core for callophycoic acids G
and H (compound 32) could also be synthesized via a bromonium-induced cation-pi
cyclization using BDSB. Thus, compound 30 was subjected to BDSB in nitromethane
and purified via preparative TLC (PTLC) to give crude compound 32 in low yield
(Figure 44).
4.3.4 Proposed endgame of the total syntheses of callophycoic acids G
(2) and H (3).
Upon the synthesis of compound 32, approaches to the endgame of the synthesis
of callophycoic acids G and H were investigated. Originally, it was proposed that
upon formation of a trans-decalin core common to all four metabolites (compound
40, Figure 38), protection of the tertiary alcohol using TBS (to form 17), followed by





































Figure 45: Natural products synthesized by Snyder’s group, all containing a similar
trans-decalin core [59, 132, 133, 134, 135, 136].
and organocuprate cross-couping would give the trans-decalin benzoate compounds
43 and 44, as shown in Figures 38 [114, 115, 59, 116, 117, 118] and Figure 46 [59,
137, 120, 138, 139, 140].
Acid hydrolysis (forming 45 or 46), followed by a Wittig reaction (forming 47
or 48), silyl ether deprotection (forming 49 or 50), and finally dehydration would
provide the target molecules 2 and 3.
However, upon further investigation of Snyder’s syntheses of peyssonol A (Figure
45) [59, 132, 133, 134, 135, 136], it was proposed that this methodology to form
peyssonol A could be applied to compounds 2 and 3. To explore this possibility, a
model system was established to optimize the endgame, as shown in Figure 47 [59].
Compounds 51 - 53 were synthesized according to previously published procedures
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00C-RT, 30m
3) 45 or 46, THF, 00C-RT, 1h
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2: Callophycoic Acid G; X = H
3: Callophycoic Acid H; X = Br
Figure 46: Initial proposed endgame for the syntheses of callophycoic acids G and
H [59, 137, 120, 138, 139, 140].
arene 7 to potentially give compound 54. Removal of the hydroxyl group should
provide the model system target 56 for callophycoic acid G [59]. Note that aldehyde
53 can also undergo nucleophilic attack by lithiated arene 10 to provide the model
system target for callophycoic acid H (57).
Specifically, optimization of coupling the benzoic acid moieties is in progress. The
nucleophilic addition method used by Snyder et al. in the synthesis of peyssonol A,
in which they used a 1,4-dibromo-2,5-bis(methoxymethoxy)benzene [59], could not
be applied to our system with benzoic acid 7, even with 2.1 equivalents of n-BuLi to
circumvent the sole deprotonation of the benzoic acid; 1H NMR analysis alluded to a
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Figure 47: Model system for the endgame of the syntheses of callophycoic acids G
and H [59].
is proposed that the methyl benzoate moiety (6 or 9) be reduced to a benzyl alcohol
(19 or 20) [141], followed by subsequent protection by converting it to a TBS ether
(21 or 22) (Figure 48) [?, 116]. Once these compound are synthesized, they can be
utilized for the synthesis of the model targets (37 and 38) for callophycoic acids G
and H (Figure 59) [59, 141]. Thus far, compounds 19 and 21 were synthesized in
moderate to high yields (99% and 59%, respectively) [?, 116].
Once the model system is established and optimized, it can be applied to the
target molecules 2 and 3 (Figures 44 and 50). Swern elimination of 32 followed by
deacetylation should give compound 33. Oxidation of 33 using Dess-Martin period-
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Figure 48: Alternative arene for the model system for the endgame of the syntheses
of callophycoic acids G and H [?, 116].
callophycoic acids G and H and callophycols A and B. Nucleophilic addition to 34
using either 7 or 10 gives benzyl alcohol 35 or 36, and hydroxyl removal should give
compounds 37 or 38 (Figure 44) [59]. Deprotection (forming 39 or 40), followed by
a Swern oxidation (to form 41 or 42), and a Wittig reaction, should provide target
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39; X = H
40; X = Br
41; X = H
42; X = Br
Br
Figure 49: Synthesis of compounds 41 and 42 [59, 120].
4.4 Conclusions
Routes toward divergent, modular, total syntheses of callophycoic acids G and H, as
well as callophycols A and B were sought in an effort to provide synthetic alternatives














2: Callophycoic Acid G; X = H
3: Callophycoic Acid H; X = Br
41; X = H
42; X = Br
Figure 50: Endgame for callophycoic acids G and H [120].
30 has been effectively synthesized (Figure 44) [59]. Investigations are currently
underway to purify trans-decalin precursor 32 (Figure 44) [59] in the progress toward
obtaining these four metabolites. Studies are also underway regarding a model system
for the endgame of these metabolites. Thus far, aldehyde 53 has been synthesized
(Figure 47) [59]; further investigations are being conducted to determine a protocol to
obtain compounds 54 and 55 to give the target models 56 and 57, respectively (Figure
47) [59]. If the syntheses of these model systems, as well as the target molecules are
successful, they can pave the way to accessing novel antibacterial agents and potential
antimalarials. In addition, the target models 56 and 57, if sythesized, could also
provide additional biologically active models.
4.5 Experimental
4.5.1 General
Reagents were purchased from commercial vendors and used as received unless other-
wise stated. All synthesized starting materials were dried under vacuum prior to use.
Anhydrous DCM was distilled from CaH2, and anhydrous THF was distilled from Na
and benzophenone. NBS was recrystallized using water. Anhydrous nitromethane
was dried using CaH2, distilled under vacuum, and stored over 4 Å molecular sieves.
K2CO3 and NaHCO3 were dried in an oven overnight and then stored in a dessicator.
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All other anhydrous solvents were purchased from commercial vendors and were sealed
under nitrogen. nBuLi (2.5 M in hexanes) was purchased from Sigma-Aldrich (St.
Louis, MO USA) and titrated against N -(3-benzylphenyl)pivalamide (recrystallized
in hexanes) prior to use. All glassware was flame dried and placed under a nitrogen
atmosphere prior to use. Purification via flash chromatography was performed using
silica gel from Dynamic Adsorbents (32-65 µm) and technical grade eluents. Thin-
layer chromatography (TLC) was conducted using EMD silica gel 60 F254 glass-backed
plates. Preparative thin-layer chromatography (PTLC) was conducted using silica gel
F254 glass-backed plates (1000 µm). For N,N -diisopropylethylamine (DIPEA)-treated
silica, untreated silica was stirred in a solution of 5% DIPEA in DCM, stirred for 30
min at room temperature, and placed under reduced pressure until dry. DIPEA-
treated silica plates were prepared by running the plates in 5% solution of DIPEA in
DCM and allowed to dry overnight. Plate visualization was accomplished using UV
light, iodine, and/or para-anisaldehyde (PAA) staining. 1H NMR spectra were ob-
tained using either a Varian Mercury Vx spectrometer (300 or 400 MHz) or a Bruker
AVII (400 or 500 MHz) spectrometer; the chemical shifts were expressed in ppm and
are referenced to the corresponding residual nuclei in the deuterated solvents. ESI-
MS/accurate mass was performed using a ThermoFisher Scientific LTQ Orbitrap XL
ETD, and EI/accurate mass analyses were performed using a Micromass AutoSpec
M. Infrared (IR) spectroscopy was accomplished by attenuated total reflection (ATR)
using a Bruker Optics Alpha-P FT-IR spectrometer.
4.5.2 Synthesis of the benzoic acid moieties of callophycoic acids G and
H
Compounds 5, 6, 8 and 9 were synthesized according to previously published proce-
dures, and the characterization data matched the data previously reported [111, 112].
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4.5.2.1 Synthesis of 3-bromo-4-(methoxymethoxy)benzoic acid 7
To a round-bottom flask, compound 6 (0.5 g, 1.82 mmol) was dissolved in 200-proof
ethanol (0.78 mL). A solution composed of potassium hydroxide (0.6119 g, 10.9 mmol)
and 200-proof ethanol (2.6 mL) was added to the above methyl ester/ethanol solution,
and the reaction mixture was allowed to stir at room temperature for 3 h. The
solvent was then removed under reduced pressure, and the residue was poured into
water, where the pH was adjusted to 5 using 10% aq. HCl. Next, the reaction
mixture was extracted 4X with DCM, dried with Na2SO4, and concentrated under
reduced pressure [113]. Purification of the crude mixture using silica gel and 5%
EtOAc/hexanes afforded compound 7 as a white solid (42% yield). 1H NMR (MeOD,
300 MHz) δ 8.34-8.24 (d, 1H), δ 7.86-7.81 (dd, 1H), δ 7.16-7.12 (d, 1H), δ5.23 (s, 2H),
δ3.38 (s, 3H). 13C NMR (MeOD, 400 MHz) δ 135.89, δ 131.60, δ 115.96, δ 95.98, δ
56.81. HRMS (EI) m/z [M]+ Calcd. for C9H9O4Br, 259.9684, found 259.9691.
4.5.3 Synthesis trans-decalin precursors
Compounds 14, 20 and 24 - 28 were synthesized according to previously published
procedures, and the characterization data matched the data previously reported [124,
125, 119, 126, 127, 120].
4.5.3.1 Synthesis of diethyl (4-(1,3-dioxolan-2-yl)-butan-2-yl)phosphonate 13
To a round-bottom flask was added diethyl ethylphosphonate (11) (0.100 g, 0.60
mmol) and THF (0.6 mL); the solution was then allowed to cool to -45◦C. nBuLi
(0.38 mL, 0.72 mmol, 1.9 M in hexanes) was added, and the reaction was allowed to
stir for 30 min at -45◦C. Then, 2-(2-bromoethyl)-1,3-dioxolane (12) was added to the
flask in one shot, and the reaction was allowed to stir for 2.5 h at room temperature.
Upon completion, the reaction was quenched with water, extracted with ethyl ether
(3X), washed with brine, dried with MgSO4, and concentrated under reduced pressure
[114]. Purification using silica gel and 0-1% MeOH/DCM afforded phosphonate 13
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as a pale yellow, viscous oil (75% yield). 1H NMR (CDCl3, 300 MHz) δ 4.86-4.77 (t,
1H), δ 4.16-3.99 (q, 4H), δ 3.98-3.77 (m, 4H), δ 1.98-1.75 (m, 2H), δ 1.75-1.58 (m,
2H), δ 1.58-1.41 (m, 1H), δ 1.33-1.24 (t, 6H), δ 1.22-1.06 (dd, 3H).
4.5.3.2 Synthesis of (2E,6E,10E)-13-(1,3-dioxolan-2-yl)-3,7,11-trimethyltrideca-
2,6,10-trien-1-yl acetate 39
To a round-bottom flask was added aldehyde 28 (0.4224 g, 1.38 mmol), ethylene
glycol (0.12 mL, 2.07 mmol), para-toluenesulfonic acid monohydrate (5.33 mg, 0.028
mmol), and benzene. A Dean-Stark trap was added, and the reaction was allowed
to reflux for 5 h or until the amount of water collected remained constant. Upon
completion, the reaction was quenched with saturated aq. NaHCO3 and concen-
trated under reduced pressure. The mixture was then extracted with EtOAc (3X),
washed with saturated aq. brine (2X), dried over anhydrous MgSO4, and concen-
trated under reduced pressure. Purification using DIPEA-treated silica gel and 5%
DIPEA/hexanes-1% EtOAc/5% DIPEA/94% hexanes produced diooxolane 39 (17%
yield). 1H NMR (CDCl3, 400 MHz), δ 5.37-5.29 (t, 1H), δ 5.18-5.04 (m, 2H), δ 4.86-
4.81 (t, 1H), δ 4.61-4.54 (d, 2H), δ 3.98-3.81 (m, 4H), δ 2.16-1.93 (m, 13H), δ 1.77-1.70
(m, 2H), δ 1.70 (s, 3H), δ 1.68 (s, 3H), δ 1.62-1.54 (m, 3H). 13C NMR (CDCl3, 400
MHz) δ 171.06, δ 142.17, δ 135.48, δ 134.33, δ 124.36, δ 124.25, δ 118.19, δ 104.29, δ
64.82, δ 61.33, δ 39.78, δ 33.82, δ 32.41, δ 26.42, δ 26.01, δ 23.33, δ 21.00, δ 16.41, δ
15.95.
4.5.3.3 Synthesis of (2E,6E,10E)-14-hydroxy-3,7,11-trimethyltetradeca-2,6,10-trien-
1-yl acetate (29)
In a round-bottom flask, aldehyde 28 (0.91 g, 2.97 mmol) was dissolved in ethyl ether
(9 mL). Sodium borohydride (0.1888 g, 4.99 mmol) was added in portions, followed by
methanol, and the reaction was stirred overnight at room temperature. Upon reaction
completion, the reaction mixture was quenched at 0◦C through the slow addition of
water. Extraction using ethyl ether, followed by drying with anhydrous MgSO4 and
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then concentration under reduced pressure, afforded the crude product [128], which
was then purified using silica gel and 10-20% EtOAc/hexanes to provide alcohol 29
as a clear, colorless oil (71% yield). 1H NMR (CDCl3, 300 MHz) δ 5.37-5.30 (t, 1H),
δ 5.20-5.05 (m, 2H), δ 4.61-4.55 (d, 2H), δ 3.66-3.59 (m, 2H), δ 2.17-1.94 (m, 15H), δ
1.69 (s, 3H), δ 1.68 (s, 3H), δ 1.62 (s, 3H). 13C NMR (CDCl3, 300 MHz) δ 171.181,
δ 142.253, δ135.471, δ 134.863, δ 125.387, δ 124.501, δ 118.188, δ 62.807, δ 61.401, δ
39.767, δ 39.481, δ 35.981, δ 30.708, δ 26.387, δ 26.050, δ 23.326, δ 21.063, δ 16.442,
δ 15.841. HRMS (EI) m/z [M]+ Calcd. for C19H32O3, 308.2351, found 308.2355. IR:
3375 (w), 2931.32 (w), 1737.63 (m), 1444.69 (w), 1365.59 (w), 1229.21 (s), 1020.96
(m) cm−1.
4.5.3.4 Synthesis of (2E,6E,10E)-14-((tert-butyldiphenylsilyl)oxy)-3,7,11-
trimethyltetradeca-2,6,10-trien-1-yl acetate (30)
To a round-bottom flask, imidazole (48.3 mg, 0.71 mmol) was dissolved in anhydrous
DMF (0.65 mL). Compound 29 was then added, and the mixture was cooled to
0◦C. TBDPSCl (0.18 mL, 0.71 mmol) was then added dropwise, and the reaction
was allowed to stir overnight at room temperature. Upon completion, the reaction
was quenched with water, extracted with ethyl ether, washed with brine, dried with
MgSO4, and concentrated under reduced pressure [129]. Purification using silica gel
and 0-1-2% EtOAc/hexanes afforded 30 as a clear, colorless oil (79% yield). 1H NMR
(CDCl3, 300 MHz) δ 7.71-7.65 (dd, 4H), δ 7.46-7.34 (m, 6H), δ 5.38-5.30 (t, 1H), δ
5.14-5.06 (t, 2H), δ 4.62-4.56 (d, 2H), δ 3.68-3.61 (m, 2H), δ 2.16-1.92 (m, 15H), δ
1.70 (s, 3H), δ 1.65 (s, 3H), δ 1.57 (s, 3H) δ 1.05 (s, 9H). 13C NMR (CDCl3, 300 MHz)
δ 171.137, δ 135.552, δ134.658, δ 134.094, δ 127.554, δ 124.252, δ 124.142, δ 123.563, δ
118.173, δ 63.803, δ 61.386, δ 45.685, δ 39.518, δ 35.805, δ 31.946, δ 30.989, δ 26.841,
δ 26.028, δ 23.046, δ 21.063, δ 19.203, δ 16.478, δ 15.914. IR: 2930.79 (w), 2875 (w),
1738.09 (m), 1427.56 (m), 1229.14 (s), 1106.96 (m), 1020.80 (w), 700.71 (s), 503.81
(m) cm−1.
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4.5.4 Endgame for callophycoic acids G and H
4.5.4.1 Synthesis of ((1R,2S,4aS,5R,6R,8aR)-6-bromo-5-(3-((tert-
butyldiphenylsilyl)oxy)propyl)-2-hydroxy-2,5,8a-
trimethyldecahydronaphthalen-1-yl)methyl acetate (32)
To a round-bottom flask was added compound 30 (73.4 mg, 0.13 mmol) and ni-
tromethane (13 mL). The mixture was allowed to cool to 0◦C, and a solution of
BDSB (81.1 mg, 0.15 mmol) in nitromethane (0.36 mL) was prepared and immedi-
ately added to the reaction flask. The reaction was stirred at 0◦C for 30 s, followed by
immediate quenching via the sequential addition of equal volumes of 5% aq. Na2SO3
and saturated aq. NaHCO3 (20 mL each). After quenching, the reaction was stirred
vigorously for 1 h at room temperature. The reaction mixture was then poured into
brine (50 mL), extracted with EtOAc (3X), washed with brine, dried with anhy-
drous MgSO4, and concentrated under reduced pressure [59] to give an orange oil
that will be carried forward to the next step without further purification. Purifica-
tion via preparative TLC (PTLC) of 20% EtOAc/hexanes (3X) provided an isomer
of compound 45 as an off-white solid (potential mixture of diastereomers). 1H NMR
(CDCl3, 400 MHz) δ 7.70-7.62 (m, 4H), δ 7.46-7.34 (m, 6H), δ 4.47-3.92 (m, 3H), δ
3.75-3.56 (m, 2H), δ 2.10-2.01 (m, 4H), δ 1.95-1.76 (m, 2H), δ 1.75-1.56 (m, 5H), δ
1.55-1.38 (m, 4H), δ 1.38-1.28 (m, 2H), δ 1.28-1.21 (m, 3H), δ 1.21-1.12 (m, 2H), δ
1.06 (s, 9H), δ 0.9 (s, 1H), δ 0.8 (s, 1H), δ 0.75-0.70 (m, 1H), δ 0.88 (s, 1H). 13C NMR
(CDCl3, 400 MHz) δ 168.00, δ135.53, δ 129.55, δ 127.59, δ72.1, δ 64.05, δ 63.21, δ
62.11, δ 59.91, δ 49.97, δ 43.57, δ 41.37, δ 40.84, δ 39.16, δ 37.87, δ 35.76, δ 30.85, δ
30.23, δ 26.81, δ 24.35, δ 21.23, δ 19.67, δ 19.13, δ 16.41.
4.5.5 Synthesis of the model system reflecting the endgame for callophy-
coic acids G and H
Compounds 51 - 53 were synthesized according to previously published procedures,
and the characterization data matched the data previously reported [59].
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4.5.5.1 Synthesis of 3-(((1S,4aR,6S,8aS)-6-bromo-5,5,8a-trimethyl-2-
methylenedecahydronaphthalen-1-yl)(hydroxy)methyl)-4-
(methoxymethoxy)benzoic acid
(54) Compound 7 (41.8 mg, 0.16 mmol) and THF (4 mL) were added to a round-
bottom flask and cooled to -78◦C. nBuLi (0.1 mL, 0.26 mmol, 2.2 M in hexanes) was
added dropwise to the benzoic acid solution, and the clear, pale, yellow mixture was
stirred for 20 min at -78◦C. Then, this lithiated benzoic acid solution was syringed
immediately into a solution of aldehyde 53 (37.7 mg, 0.12 mmol) at -40◦C and stirred
for 20 min and then quenched via the sequential addition of equal volumes of saturated
aq. NH4Cl and water (5.8 mL each). The reaction mixture was extracted with EtOAc
(3X), washed with brine, dried using MgSO4, concentrated under reduced pressure
[59] and carried forward to the next step without further purification.
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5.1 Enantiopure and non-enantiopure Co(III)-salen cata-
lysts and the effects of the counter-ion on hydrolytic
kinetic resolution (HKR) reactions
The work involving the catalysis of the HKR of epichlorohydrin using 50% enan-
tiopure ligand with a counter-ion constructed to make the salen complex nucleophile-
delivering (e.g., −OH) and 50% racemic ligand with a counter-ion constructed to make
the salen complex a Lewis acidic, electrophilic complex (e.g., SbF6
−) was conducted.
The goal of these studies was to determine whether high activity and enantioselectiv-
ity could be achieved for HKR that is comparable to a catalyst system composed of
both (R,R)-Co-salen-OH and (R,R)-Co-salen-SbF6 complexes [84], thus lowering the
cost of the reactions. It was shown that the catalysis systems containing only 50%
enantiopure ligand did not lead to enantioselective catalysis, which was a result of the
scrambling of the counter-ions between the Co-centers, as was reflected via kinetic
studies, EA, and FT-IR [84].
In conducting the experiments to confirm the counter-ion exchange in the afore-
mentioned catalytic systems, it was discovered that oxidation of a Co(II) on a poly-
mer support can occur via exposure to a homogeneous Co(III) species [84]. This not
only further exemplified the counter-ion exchange but it also exhibits potential to
serve as a method for regenerating the Co(III)-salen catalysts that are deactivated
throughout the course of HKR due to counter-ion loss [83]. To further investigate
these observations, HKR reactions were performed using a 1:1 ratio of homogeneous
(R,R)-Co(II)-salen (1) and homogeneous (R,R)-Co(III)-salen-SbF6 (2) (Figure 51)
to study the reaction kinetics [142]; this catalytic system provided high initial TOFs
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(2.6 min−1) as well as displayed high enantioselectivity, reaching 99% ee in 90 min
[142]. When tested with a 1:1 ratio of polymer resin-supported Co(II)-salen and ho-
mogeneous (R,R)-Co(III)-salen-SbF6 (2), though not as active or selective as the case
using all homogeneous Co complexes, slightly higher initial TOFs (4.02 min−1) were
obtained, reaching >99% ee in 3 h (Figure 51) [142]; this is comparable to the kinetic
data shown in Chapter 2 (Table 3, entry 3), where a 1:1 mixture of (R,R)-Co(III)-
salen-Cl and (R,R)-Co(III)-salen-SbF6 was used [142]. This further supports the fact
that the Co(II) plays a role in the catalysis of HKR. Thus, future work pertaining
to the Co-salen-catalyzed HKR studies described in Chapter 2 could involve deter-
mining the specific role and/or reaction order on the homogeneous and supported
Co(II)-salen catalysts and whether the rate of HKR coincided with the overall Co
content in the system.
Although the role of the Co(II) has yet to be determined (to our knowledge) in
HKR, Feng et al. investigated the role of polymer resin-supported Co(II)-salens in
the regioselective ring-opening of 1,2-epoxyhexane using methanol (Figure 52) [143].
In this study, a poly(styrene)-supported salen ligand with various Co loadings (4a-
4c, as well as a varying SbF6
− counter-ion content), was used (Figure 52 and Table 6)
[143]. In the ring-opening reactions, polymer resin-supported catalysts that had the
greatest overall Co content (e.g., Co(II) + Co(III)) exhibited faster activities than
the polymer resin-supported catalyst that had a greater amount of Co(III) species
present, as catalyst 4a-SbF6 reacted twice as fast as catalyst 4b-SbF6 (initial TOF
= 0.9 min−1) [143]. Thus, the overall Co composition does play a role in the alcohol
ring-opening (ARO) catalysis, which is supported by the fact that the reaction order
was found to be approximately 0.1 with respect to the Co(II) species [143]. Thus, as
previously mentioned, using a similar approach in the catalyst design for applications
in HKR to determine the role of the Co(II) species could shed further knowledge and
































Figure 51: HKR of racemic ECH comprising a 1:1 ratio of homogeneous (R,R)-
Co(III)-salen-SbF6 and either homogeneous or polymer resin-supported (R,R)-
Co(II)-salen [142].
The above-proposed investigations into HKR and ARO are regarding the more
Lewis acidic salen, which has a non-coordinating SbF6
− counter-ion. However, there
have been no investigations thus far concerning the oxidation of polymer-supported
Co-salens such that a nucleophile-delivering salen complex is formed. Therefore, re-
actions regarding HKR catalysis using supported Co(III)-salen-X (X = nucleophilic
counter-ion, such as Cl, OAc) with varying degrees of oxidation could be conducted to
determine whether catalysis using these Co-salens with a nucleophile-delivering com-
plex are also dependent on the overall Co content. Studies investigating both types
of counter-ions (nucleophilic and non-nucleophilic) could provide further insights into
























Figure 52: Regioselective ring opening of 1,2-epoxyhexane using methanol [143].
Table 6: Elemental analysis data from the catalysts used for the regioselective ring-
opening of 1,2-epoxyhexane using methanol. Data from Ref. [143].
Entry Catalyst N (%) Sb (%) Co (%) N/Co Co loading (%) Co/Sb Co oxidized (%)
1 4a-SbF6 1.8 0.25 0.53 2.4 83 2.1 48
2 4b-SbF6 1.8 0.26 0.37 3.5 57 1.4 71
3 4c-SbF6 1.7 0.15 0.17 7.1 28 1.1 91
Based on the findings in Chapter 2, it was suggested that this oxidation of a Co(II)
species via a homogeneous Co(III) species could provide a method for catalyst regen-
eration after deactivation by counter-ion loss [83]. Venkatasubbaiah et al. investigated
the recycling and regeneration of polymer resin-supported Co(III)-salen-X catalysts,
where X = OAc (5), camphorsulfonate (CSA) (6), and BF4
− (7) (Figure 53) [83]; it
was determined that the deactivation of the catalyst was counter-ion dependent (e.g.,
the catalyst containing the BF4
− counter-ion was stable over three cycles, with the
initial TOF decreasing from 6.23 to 5.89 min−1), and the regeneration of the polymer-
supported Co(III)-salen-CSA using camphorsulfonic acid in toluene led to significant
metal leaching due to possible ligand hydrolysis [83]. Thus, a method to regenerate
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these catalysts while avoiding ligand hydrolysis would be ideal. The results obtained
in Chapter 2 showed oxidation of a polymer-supported Co(II)-salen via contact of a
homogeneous (R,R)-Co(III)-salen-SbF6 [84], which is not a proton source. Although
previous studies showed that regeneration of a polymer-supported Co(III)-salen-SbF6
using lutidinium-SbF6 (LuSbF6) did result in further metal leaching in the recycled
catalysts [143], using a lutidinium derivative, such as a lutidinium camphorsulfonate,
could result in a smaller degree of metal leaching due to ligand hydrolysis because it is
a weaker Bronsted acid relative to camphorsulfonic acid. If using a lutidinium source
as an alternative to strong carboxylic acids, such as camphorsulfonic acid, leads to
more effective catalyst regeneration, then this could provide and lead to more effective
methods for catalyst regeneration, as there is a need for well-developed methods for
supported catalyst regeneration because this is currently a drawback regarding their





















X = OAc (5), CSA (6), BF4
- (7)
Figure 53: HKR of racemic epichlorohydrin using polymer resin-supported Co(III)-
salen-X (X = OAc, CSA, BF4
−) to investigate the recyclability of the catalysts, as
well as the effectiveness of catalyst regeneration methods [83].
The aforementioned research regarding HKR involved studying it from a catal-
ysis science perspective. As mentioned in the previous chapters, HKR can be used
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as a method to synthesize chiral building blocks that might otherwise be inacces-
sible. In the following research involving the progress in the natural product total
synthesis of metabolites isolated from Callophycus serratus, there is a need for chiral
intermediates, where methods such as HKR can be utilized.
5.2 Callophycolide A
As previously described, of the 17 proposed steps required to accomplish the total
synthesis of callophycolide A, eight of these steps were successfully completed. The
major limiting factor for this synthesis regards the synthesis of compound 22: the
base-promoted ERO (Figure 54). Therefore, if this total synthesis was to be revisited,
this step should be taken into consideration. First, the model system using ((2-
methylallyl)sulfonyl)benzene 14 and styrene oxide to form 15 (Figure 55) [109, 110]
should be performed in an atmosphere that is free of air and moisture. The reaction
to form 16 was performed using Schlenk conditions; the nBuLi was titrated against
a recrystallized indicator; the THF was freshly distilled; and the starting materials
were confirmed to have no water contamination. However, this was not sufficient
for obtaining a high yield of pure product. Thus, it is recommended that these
reactions be performed in a glove box such that no air/moisture enter the system,
thus potentially leading to a higher yield of pure product. Once this step is optimized,
the ERO can be performed for the actual system, thus forming compound 22 (Figure
56) [57, 100, 102, 110, 109, 144, 145]. Subsequently, saponification, sulfone removal,
Steglich esterification, and then global MOM deprotection should afford the desired





































































Figure 55: Scheme of the ERO model system, which should result in the formation




















































1) iPrMgCl, 1h, -15oC













Figure 56: Proposed callophycolide A endgame [57, 100, 102, 110, 109, 144, 145].
As mentioned previously, concerning callophycolide A, there are two stereocenters
present in the molecule. When Stout et al. first isolated callophycolide A, the absolute
configuration of C-14 was confirmed as S by Mosher’s ester analysis, 1H NMR, HSQC-
TOCSY, and ∆δS-R calculations (Figure 57) [54, 146]. However, circular dichroism
(CD) and NOE studies were only able to strongly suggest that the absolute config-
uration at C-15 was R (Figure 57) [54]. Therefore, not only will the total synthesis
of callophycolide A serve as a template for the syntheses of more potent antimalar-
ials but it can also lead to the synthesis of the diastereomers and enantiomers of
the previously reported callophycolide A; an examination of the biological activities
of these isomers will not only give rise to potentially potent synthetic derivatives of
callophycolide A but the biological activity studies will also aid in the conformation







Configuration strongly suggested to be 15R
Figure 57: Figure depicting the configurations of the C-14 and C-15 stereocenters of
callophycolide A [54].
5.3 Callophycoic Acids G and H
As mentioned in the previous chapter, efforts were made to develop a pathway to
synthesize a common trans-decalin precursor, which can be used for the syntheses of
callophycoic acids G and H and callophycols A and B. Although these metabolites
display modest biological activities against bacteria, cancer, and malaria [55], this
modular approach to access these compounds could serve as a template to synthesize
the more potent metabolites of C. serratus.
5.3.1 trans-Decalin syntheses
5.3.1.1 Model system for the synthesis of callophycoic acids G and H
As mentioned previously, investigations are underway on a model system to determine
the endgame of callophycoic acids G and H. These investigations involve forming the
trans-decalin core and functionalizing this core with the appropriate benzoic acid
moiety (Figure 58) [59].
Specifically, optimization of coupling the benzoic acid moieties is in progress. The
nucleophilic addition method used by Snyder et al. in the synthesis of peyssonol A, in
which they used a 1,4-dibromo-2,5-bis(methoxymethoxy)benzene [59], could not be



















































30; X = H
31; X = Br
27 28
29
32; X = H
33; X = Br
34; X = H
35; X = Br
Br
Figure 58: Model system for the endgame of the syntheses of callophycoic acids G
and H [59].
circumvent the sole deprotonation of the benzoic acid; 1H NMR analysis alluded to
a symmetrical arene, which does not correspond to the desired product. Therefore,
it is proposed that the methyl benzoate moiety (36 or 37) be reduced to a benzyl
alcohol (38 or 39) [141], followed by subsequent protection by converting it to a TBS
ether (40 or 41) (Figure 59) [59, 141]. Once these compound are synthesized, they
can be subjected to lithiation, followed by nucleophilic addition to aldehyde 29, to
obtain the benzyl alcohol (42 or 43) ; removal of this benzyl alcohol (to form 44 or
45), followed by removal of the TBS group using TBAF (to form 46 or 47), and then
oxidation to yield the model target (37 or 38) for callophycoic acids G and H (Figure
59) [59, 141].
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38; X = H
39; X = Br
40; X = H




42; X = H
43; X = Br
44; X = H
45; X = Br
46; X = H
47; X = Br
37; X = H
38; X = Br
DCM, NEt3
Figure 59: Revised model system for the endgame of the syntheses of callophycoic
acids G and H [141, 59].
acids G and H, the MOM-protected tribromophenol (50) can also undergo lithiation,
followed by nucleophilic attack to aldehyde 29, which will correspond to the phenol
head of callophycols A and B (Figure 60) [59]. The successful syntheses of these
target models for callophycoic acids G and H and callophycols A and B will not only
aid in the total syntheses of the desired target molecules; if effectively isolated and
characterized, these molecules could also be tested for biological activity, thus leading
to other pharmaceutical treatments via a natural product or derivatives. Because
similar structures with the arene head groups and the trans-decalin cores exhibit
activity against allosteric inhibitors of HIV transcriptase, such as peyssonol A [132,
133], and bacteria, such as peyssonoic acid A [134] and the callophycoic acids G and


































































Figure 60: Model system for the endgame of the syntheses of callophycols A (4) and
B (5) [59].
5.3.2 Syntheses of callophycoic acids G and H
Regarding compound 55, efforts have been made to form this trans-decalin needed
for callophycoic acids G and H according to the aforementioned procedures (Figure
61) [59]. In isolating the reaction components via flash column chromatography and
PTLC, the preliminary conclusions drawn are that an isomer of 55 was synthesized;
however, the product obtained via flash column chromatography and PTLC (at the
upper limit) has been impure. To be able to effectively isolate compound 55, op-
timization of the purification conditions, such as decreasing the sample loading of
PTLC, or exploring recrystallization techniques, should result in a pure compound
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55 or one of its pure isomers. Reactions are currently underway where the crude
trans-decalin 55 will be carried forward to carry out the Swern elimination, followed
by acetate removal to form compound 56 (Figure 61) [59]. Although the syntheses to
form compound 56 will most likely result in a mixture of isomers, this approach does
carry merit. First, if these isomers can be separated, then the callophycoic acids G
and H could still be isolated. Second, syntheses and characterization of diastereomers































40; X = H
41; X = Br
58; X = H
59; X = Br
1) 40 or 41
60; X = H












































62; X = H
63; X = Br
64; X = H
65; X = Br
Br
Figure 61: Progress toward the synthesis of compounds 64 and 65 [59].
With compound 56, oxidation should give aldehyde 57, which can be coupled
to 40 or 41 to give 58 or 59, respectively (Figure 61) [59]. Removal of the benzyl
alcohol (to form 60 and 61), followed by deprotection (to form 62 and 63), oxidation
(to form 64 and 65) (Figure 61) [59], and finally, a Wittig reaction, should provide
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9: Callophycoic Acid G; X = H
10: Callophycoic Acid H; X = Br
64; X = H
65; X = Br
Figure 62: Endgame for callophycoic acids G and H [120].
5.3.3 Callophycols A and B
Callophycols A and B are halogenated diterpene-phenols, also isolated from C. ser-
ratus, as are the other natural products discussed in the current studies. Not only do
they share the same trans-decalin core as the callophycoic acids G and H but they
also exhibit modest antimalarial activity (IC50 = 35.7 µM (A) and 40.4 µM (B)) [55].
Due to this common identical core, if a divergent total synthesis of the callophycoic
acids G and H can be established, it can serve as a template for callophycols A and
B.
Evaluating the retrosynthetic analyses of callophycols A and B, both of the com-
pounds can be synthesized via the appropriate vicinal dehydrohalogenation of trisub-
stituted olefin 66, as shown in Figure 63. Olefin 66 can be synthesized via a Wittig
reaction of compound 67, which is formed via the nucleophilic addition of MOM-
protected-2,4-6-tribromophenol (50) and the trans-decalin 57, which was also used
in the syntheses of callophycoic acids G and H; thus, the same synthetic steps can be
used, starting with geranyllinalool 70, as shown in Figure 64.
Regarding the current progress toward the syntheses of callophycols A and B,














Callophycol A: 11; X1 = Br, X2 = Cl




















9: Callophycoic Acid G; X = H











38; X = H
39; X = Br
64; X = H





Figure 63: Retrosynthetic analyses of callophycols A and B and callophycoic acids
G and H, part 1.
tribromophenol (50) (Figure 60) [59, 147]. Therefore, of the 20 steps needed to
achieve each of these syntheses, 9 steps have already been completed. As mentioned,
investigations of the model systems for callophycols A and B are currently underway,
and compounds modeling structures 56 and 57 have been achieved (Figure 60) [59].
Moreover, in regards to the vicinal dihalogenation, a vicinal dihalide was previously
synthesized in two steps from the commercially available 6-methyl-5-hepten-2-one
(71) (Figure 65) [148, 149].
Based on 1H NMR, 13C NMR, and ESI-MS, the bromochloro compound 73 was



























Figure 64: Retrosynthetic analyses of callophycols A and B and callophycoic acids
G and H, part 2.
experiments for the vicinal dihalogenation of compound 69 will be conducted to first
determine if the above conditions will provide the respective trans-decalin precursor
for callophycols A and B. If this vicinal dihalogenation is successful, then this will




































EXPERIMENTAL PROTOCOLS FOR COMPOUNDS IN
CO(III)-SALEN-CATALYZED HKR AND THE
SYNTHESES OF DITERPENES ISOLATED FROM C.
SERRATUS
A.1 Co(III)-salen-catalyzed HKR (refer to Chapter 2 for
the numbering of compounds)
Homogeneous catalysts 1 - 4 were prepared according to previously published proce-
dures [72, 73]. Polymer resin-supported catalyst 8 was prepared according to previ-
ously published procedures [81, 82, 83]. Styrene/DVB resin was synthesized according
to previously published procedures [82].
A.2 Callophycolide A (1) (refer to Chapter 3 for the num-
bering of compounds)
Compounds 5, 6, 8-12, 20-22 and 24 were prepared according to previously pub-



































































































































































































































































































































































Figure 67: 1H NMR spectrum of 4-methyl-1-phenyl-3-(phenylsulfonyl)pent-4-en-1-ol
(26).
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A.3 Callophycoic Acids G (2) and H (3), refer to Chapter
4 for the numbering of compounds
Compounds 5, 6, 8 and 9 were synthesized according to previously published proce-
dures [111, 112].
Compounds 14, 20 and 24 - 28 were synthesized according to previously published
procedures [124, 125, 119, 126, 127, 120].































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Reagents were purchased from commercial vendors and used as received unless other-
wise stated. All synthesized starting materials were dried under vacuum before use.
Anhydrous THF was distilled from Na and benzophenone. All glassware was flame
dried and placed under a nitrogen atmosphere prior to use. Purification via flash
chromatography was performed using silica gel from Dynamic Adsorbents (32-65µm)
and technical grade eluents. Thin-layer chromatography (TLC) was conducted using
EMD silica gel 60 F254 glass-backed plates. Plate visualization was accomplished us-
ing vanillin staining. NMR spectra were obtained using either a Varian Mercury Vx
spectrometer (300 or 400 MHz) or a Bruker AVII (400 or 500 MHz) spectrometer; the
chemical shifts were expressed in ppm and are referenced to the corresponding resid-
ual nuclei in the deuterated solvents. ESI-MS/accurate mass was performed using
a ThermoFisher Scientific LTQ Orbitrap XL ETD, and EI/accurate mass analyses
were performed using a Micromass AutoSpec M.
A.6.1 Synthesis of 2-(3-bromo-4-chloro-4-methylpentyl)-2-methyl-1,3-
dioxolane (73).
To a round-bottom flask was added N -bromoacetamide (0.2028 g, 1.47 mmol), LiCl
(62.3 mg, 1.47 mmol), and anhydrous THF (1.8 mL). The flask was cooled to 0◦C, and
the reaction was allowed to stir at 0◦C for 2 h and then at room temperature for 22
h. Upon completion, the reaction mixture was concentrated under reduced pressure,
and the residue was diluted with ether, extracted with ether, washed with brine, dried
with anhydrous Na2SO4, and concentrated under reduced pressure. Purification using
silica gel and 3-4% EtOAc/hexanes afforded impure compound 73 (19% yield). 1H
NMR (CDCl3, 300 MHz) δ 4.32-4.26 (dd, 1H), δ 4.16-4.11 (dd, 1H), δ 3.98-3.94 (m,
8H), δ 2.63-2.52 (m, 1H), δ2.52-2.40 (m, 1H), δ 2.34-2.20 (m, 2H), δ 1.92 (s, 3H), δ
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1.96-1.83 (m, 2H), δ 1.82 (m, 3H), δ 1.78 (s, 6H), δ 1.76-1.68 (m, 2H), δ 1.65 (s, 3H),
δ 1.35 (d, 6H). 13C NMR (CDCl3, 300 MHz) δ 109.75 δ 72.042, δ 68.644, δ 67.018, δ
66.132, δ 64.740, δ 64.550, δ 37.497, δ 37.431, δ 33.161, δ 30.657, δ 29.185, δ 28.123,
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